CN115245549B - A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis - Google Patents
A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis Download PDFInfo
- Publication number
- CN115245549B CN115245549B CN202210973140.1A CN202210973140A CN115245549B CN 115245549 B CN115245549 B CN 115245549B CN 202210973140 A CN202210973140 A CN 202210973140A CN 115245549 B CN115245549 B CN 115245549B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- constitution
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 306
- 239000000203 mixture Substances 0.000 title claims abstract description 156
- 201000005569 Gout Diseases 0.000 title claims description 13
- 206010018634 Gouty Arthritis Diseases 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 74
- 239000002994 raw material Substances 0.000 claims abstract description 62
- 241000132012 Atractylodes Species 0.000 claims abstract description 39
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 25
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 21
- 240000000031 Achyranthes bidentata Species 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims description 121
- 239000002552 dosage form Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 57
- 230000009466 transformation Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 15
- 230000001105 regulatory effect Effects 0.000 abstract description 14
- 230000007774 longterm Effects 0.000 abstract description 5
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 87
- 210000000952 spleen Anatomy 0.000 description 61
- 230000007812 deficiency Effects 0.000 description 52
- 210000004185 liver Anatomy 0.000 description 48
- 210000004072 lung Anatomy 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 238000001467 acupuncture Methods 0.000 description 31
- 241000220317 Rosa Species 0.000 description 27
- 210000002784 stomach Anatomy 0.000 description 27
- 241000202726 Bupleurum Species 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- 244000303040 Glycyrrhiza glabra Species 0.000 description 25
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 238000003756 stirring Methods 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 24
- 235000009508 confectionery Nutrition 0.000 description 23
- 208000011580 syndromic disease Diseases 0.000 description 23
- 241001061264 Astragalus Species 0.000 description 22
- 240000005373 Panax quinquefolius Species 0.000 description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 description 22
- 235000006533 astragalus Nutrition 0.000 description 22
- 210000004233 talus Anatomy 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- 239000000284 extract Substances 0.000 description 21
- 239000000843 powder Substances 0.000 description 21
- 241000675108 Citrus tangerina Species 0.000 description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 20
- 235000008434 ginseng Nutrition 0.000 description 20
- 239000004831 Hot glue Substances 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 18
- 241000234653 Cyperus Species 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 15
- 241001180873 Saposhnikovia divaricata Species 0.000 description 15
- 210000000038 chest Anatomy 0.000 description 15
- 229940010454 licorice Drugs 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 244000052909 Dioscorea esculenta Species 0.000 description 14
- 235000011158 Prunus mume Nutrition 0.000 description 14
- 244000018795 Prunus mume Species 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 241000132011 Atractylodes lancea Species 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 238000005728 strengthening Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 244000131316 Panax pseudoginseng Species 0.000 description 12
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 239000010135 fructus aurantii immaturus Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 210000000232 gallbladder Anatomy 0.000 description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 10
- 235000011477 liquorice Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- 210000000582 semen Anatomy 0.000 description 10
- 206010010774 Constipation Diseases 0.000 description 9
- 235000018958 Gardenia augusta Nutrition 0.000 description 9
- 240000001972 Gardenia jasminoides Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000032023 Signs and Symptoms Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 210000001835 viscera Anatomy 0.000 description 9
- 235000016854 Cyperus rotundus Nutrition 0.000 description 8
- 244000075634 Cyperus rotundus Species 0.000 description 8
- 239000002390 adhesive tape Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 244000183685 Citrus aurantium Species 0.000 description 7
- 235000007716 Citrus aurantium Nutrition 0.000 description 7
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 7
- 235000006886 Zingiber officinale Nutrition 0.000 description 7
- 230000006837 decompression Effects 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 235000008397 ginger Nutrition 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 230000035900 sweating Effects 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 6
- 235000016646 Citrus taiwanica Nutrition 0.000 description 6
- 208000035240 Disease Resistance Diseases 0.000 description 6
- 235000010254 Jasminum officinale Nutrition 0.000 description 6
- 240000005385 Jasminum sambac Species 0.000 description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000021251 pulses Nutrition 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 240000004307 Citrus medica Species 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 241001038563 Pseudostellaria Species 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 241001164374 Calyx Species 0.000 description 4
- 241000209205 Coix Species 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 4
- 244000236658 Paeonia lactiflora Species 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 230000008407 joint function Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000037368 penetrate the skin Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 241001127714 Amomum Species 0.000 description 3
- 244000061520 Angelica archangelica Species 0.000 description 3
- 241000489492 Arisaema Species 0.000 description 3
- 241000092665 Atractylodes macrocephala Species 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 244000281702 Dioscorea villosa Species 0.000 description 3
- 208000002513 Flank pain Diseases 0.000 description 3
- 235000004036 Glehnia littoralis Nutrition 0.000 description 3
- 244000146486 Glehnia littoralis Species 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 206010051602 Laziness Diseases 0.000 description 3
- 241001180876 Saposhnikovia Species 0.000 description 3
- 206010040952 Skin warm Diseases 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 201000001352 cholecystitis Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000004879 dioscorea Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000012943 hotmelt Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000013077 scoring method Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- 241000510654 Bupleurum chinense Species 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 235000002723 Dioscorea alata Nutrition 0.000 description 2
- 235000007056 Dioscorea composita Nutrition 0.000 description 2
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 2
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 2
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 2
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 2
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 235000006751 Platycodon Nutrition 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 240000002505 Pogostemon cablin Species 0.000 description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 210000002468 fat body Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229930189914 platycodon Natural products 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000206501 Actaea <angiosperm> Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000141331 Amomum villosum Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000587240 Cynanchum Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 244000118681 Iresine herbstii Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000002563 stool test Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种改善湿热体质的中药组合物及其制备方法和应用,所述的中药组合物由以下重量份的原料药制成:苍术10‑20份、怀牛膝10‑20份、薏苡仁10‑20份、厚朴10‑20份、天竺子10‑20份、制胆星10‑20份。本发明中药组合物穴位敷贴由所述中药组合物按1:1:1:1:1:1的比例组成,选穴以阳陵泉、支沟、曲泉为主。本发明中药组合物有携带方便,安全无毒的特点,适用于任何人群,尤其适宜于湿热体质者,坚持长期规律贴敷,对改善湿热体质,调理机体整体状态有着明显的效果,促进湿热体质向平和质状态转变。The invention relates to a traditional Chinese medicine composition for improving damp-heat constitution and its preparation method and application. The traditional Chinese medicine composition is made of the following raw materials in parts by weight: 10-20 parts of atractylodes rhizome, 10-20 parts of Achyranthes bidentata, 10-20 parts of coix seed, 10-20 parts of magnolia officinalis, 10-20 parts of Tianzhuzi, and 10-20 parts of Zhidanxingxing. The acupoint application of the traditional Chinese medicine composition of the present invention is composed of the traditional Chinese medicine composition in a ratio of 1:1:1:1:1:1, and the selected acupoints are mainly Yanglingquan, Zhigou and Ququan. The traditional Chinese medicine composition of the present invention has the characteristics of easy carrying, safety and non-toxicity, and is suitable for any crowd, especially suitable for those with damp-heat constitution. Adhering to long-term regular application has obvious effects on improving damp-heat constitution and regulating the overall state of the body, and promoting the transformation of damp-heat constitution into a peaceful state.
Description
技术领域Technical Field
本发明涉及中药技术领域,具体地说,是关于一种改善体质的中药组合物。The present invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for improving physical fitness.
背景技术Background Art
关于“体质”的理论起源于《黄帝内经》。2009年4月中华中医药学会在《中医体质分类与判定》上将体质分为:平和质、气虚质、阳虚质、阴虚质、痰湿质、湿热质、血瘀质、气郁质、特禀质。中医研究认为,中医体质是指人体在先天禀赋和后天获得的基础上所形成的形态结构、生理功能和心理状态方面的固有特质,具有综合性、相对稳定性,往往决定着人体对生理反应的特异性,及对某些致病因子的易感性与产生病变类型的倾向性,从而影响后天疾病的证候类型及病情转归。The theory of "constitution" originated from the Yellow Emperor's Classic of Internal Medicine. In April 2009, the Chinese Association of Traditional Chinese Medicine divided constitution into the following categories in the "Classification and Determination of Constitution in Traditional Chinese Medicine": peaceful constitution, qi deficiency constitution, yang deficiency constitution, yin deficiency constitution, phlegm-damp constitution, damp-heat constitution, blood stasis constitution, qi stagnation constitution, and special constitution. According to TCM research, TCM constitution refers to the inherent characteristics of the human body in terms of morphological structure, physiological function and psychological state formed on the basis of innate endowment and acquired acquisition. It is comprehensive and relatively stable, and often determines the specificity of the human body's physiological response, susceptibility to certain pathogenic factors and tendency to produce pathological types, thereby affecting the syndrome type and disease outcome of acquired diseases.
湿热体质中,所谓湿,即通常所说的水湿,它有外湿和内湿的区分。外湿是由于气候潮湿或涉水淋雨或居室潮湿,使外来水湿入侵人体而引起;内湿是一种病理产物,常与消化功能有关。中医认为脾有“运化水湿”的功能,若体虚消化不良或暴饮暴食,吃过多油腻、甜食,脾不能正常运化而使“水湿内停”;且脾虚的人也易招来外湿的入侵,外湿也常困阻脾胃使湿从内生,所以两者是既独立又关联的。所谓热,则是一种热象。而湿热中的热是与湿同时存在的,或因夏秋季节天热湿重,湿与热合并入侵人体,或因湿久留不除而化热,或因“阳热体质”而使湿“从阳化热”,因此,湿与热同时存在很常见。In damp-heat constitution, dampness is what is commonly referred to as water dampness, which can be divided into external dampness and internal dampness. External dampness is caused by external water dampness invading the human body due to damp climate, wading in the rain, or dampness in the house; internal dampness is a pathological product, often related to digestive function. Traditional Chinese medicine believes that the spleen has the function of "transporting and transforming water dampness". If the body is weak and has indigestion or overeating, eating too much greasy and sweet food, the spleen cannot normally transport and transform it, causing "water dampness to stagnate inside"; and people with spleen deficiency are also prone to invasion of external dampness, which often blocks the spleen and stomach and causes dampness to be generated from the inside, so the two are both independent and related. The so-called heat is a kind of heat phenomenon. The heat in damp-heat exists at the same time as dampness, or because it is hot and humid in summer and autumn, dampness and heat invade the human body together, or because dampness is left for a long time and turns into heat, or because of "yang heat constitution", dampness "turns into heat from yang", so it is common for dampness and heat to exist at the same time.
中医体质穴位敷贴是将中药研末调制成药膏后贴敷在体表穴位的一种外治法,是中医从古至今常用的外治法之一。中医体质穴位贴疗法是基于中医药理论的指导下,根据“内病外治”的原则,利用相对应体质类型的中药,配以辛温、走窜、通经之药物贴敷于相关穴位,使药物透过皮肤腠理进入穴位经络,通过经络气血的运行作用,发挥药物的“归经”和功能效应,直达相关脏腑,旨在调整机体体质,增强抗病能力。本法多用气味倶厚中药结合体表经络穴位给药,通过药物经皮渗透吸收及腧穴特异性治疗发挥疗效。即药物经皮肤和粘膜的吸收,一部分直接作用于体表穴位,刺激穴位及经络;另一部分吸收进入全身血液循环达到有效血药浓度以发挥作用。TCM acupoint patch therapy is an external treatment method that grinds Chinese medicine into ointment and then applies it to the acupoints on the body surface. It is one of the external treatment methods commonly used in TCM from ancient times to the present. TCM acupoint patch therapy is based on the guidance of TCM theory and the principle of "external treatment of internal diseases". It uses Chinese medicine of corresponding constitution type, with pungent and warm, running and meridian-draining drugs, and applies them to relevant acupoints, so that the drugs can enter the acupoints and meridians through the skin pores, and exert the "return to meridians" and functional effects of the drugs through the running of meridian qi and blood, directly reaching the relevant internal organs, aiming to adjust the body constitution and enhance disease resistance. This method uses Chinese medicine with strong smell and combined with acupoints on the body surface to administer drugs, and exerts its efficacy through transdermal penetration and absorption of drugs and acupoint-specific treatment. That is, the drugs are absorbed through the skin and mucous membranes, part of which directly acts on the acupoints on the body surface to stimulate the acupoints and meridians; the other part is absorbed into the systemic blood circulation to reach an effective blood drug concentration to exert its effect.
中国专利文献CN111450205A公开了一种调治湿热体质的中药组合物及其制剂和应用,所述中药组合物的活性组分包括以下重量份的原料药:黄芪150-450份、白术100-300份、苍术80-120份、太子参50-150份、山药70-230份、莲子80-130份、白扁豆80-120份、茯苓50-150份、藿香80-30份、佩兰80-120份、薏仁250-350份、蒲公英150-450份、山楂70-120份、决明子80-130份、荷叶70-130份、陈皮80-120份、金银花80-120份、谷芽80-120份、枳壳150-250份、桔梗70-130份、甘草40-80份、鸡内金80-120份、槐花80-120份、厚朴花100-300份、白芍50-150份、黄连25-40份、茯神80-120份。诸药合奏化湿清热之功,对湿热体质有显著的调治效果,恢复且较长时间保持比较健康的平和质。中国专利文献CN104524110A公开了一种具有健脾祛湿作用的中药组合物。该中药组合物的原料药包括薏苡仁、赤小豆、芡实、山药和苦杏仁,还可以包括广藿香和金银花。本发明中药组合物经临床观察,具有调养脾胃,祛湿清热之功,并能调整偏湿热体质,健脾祛湿效果显著。本发明的组合物服用方便,符合现代人的快节奏生活需求,并且安全有效,无任何毒副作用。但是关于本发明一种改善湿热体质的中药组合物及其制备方法和应用目前还未见报道。Chinese patent document CN111450205A discloses a Chinese medicine composition for treating damp-heat constitution, its preparation and application. The active components of the Chinese medicine composition include the following raw materials in parts by weight: 150-450 parts of Astragalus, 100-300 parts of Atractylodes, 80-120 parts of Atractylodes, 50-150 parts of Pseudostellaria, 70-230 parts of Dioscorea, 80-130 parts of Lotus Seed, 80-120 parts of White Lablab, 50-150 parts of Poria, 80-30 parts of Patchouli, 80-120 parts of Cyperus, 20 parts of Coix Seed. 50-350 parts, 150-450 parts of dandelion, 70-120 parts of hawthorn, 80-130 parts of cassia seed, 70-130 parts of lotus leaf, 80-120 parts of dried orange peel, 80-120 parts of honeysuckle, 80-120 parts of malt sprout, 150-250 parts of bitter orange, 70-130 parts of platycodon, 40-80 parts of liquorice, 80-120 parts of chicken gizzard, 80-120 parts of sophora japonica, 100-300 parts of magnolia officinalis flower, 50-150 parts of white peony root, 25-40 parts of coptis root, 80-120 parts of poria. All the medicines work together to remove dampness and clear away heat, and have a significant regulating effect on damp-heat constitution, restoring and maintaining a relatively healthy and peaceful quality for a long time. Chinese patent document CN104524110A discloses a Chinese medicine composition with the effect of strengthening the spleen and removing dampness. The raw materials of the Chinese medicine composition include coix seed, red bean, Euryale ferox, yam and bitter almond, and may also include patchouli and honeysuckle. The Chinese medicine composition of the present invention has the functions of regulating the spleen and stomach, removing dampness and clearing heat, and can adjust the damp-heat constitution, and has a significant effect of strengthening the spleen and removing dampness. The composition of the present invention is easy to take, meets the fast-paced life needs of modern people, and is safe and effective without any toxic and side effects. However, there is no report on a Chinese medicine composition for improving damp-heat constitution of the present invention, its preparation method and application.
气郁体质(Qi depression constitution)是由于长期情志不畅、气机郁滞而形成的以性格内向不稳定、忧郁脆弱、敏感多疑为主要表现的体质状态。处于这种体质状态者,多见于中青年,以女性多见,性格多孤僻内向,易多愁善感,气量较狭小。气郁体质者的发病以肝为主,兼及心、胃、大肠、小肠。易伤情志及饮食,易产生气机不畅,如郁病、失眠、梅核气、惊恐等,现代研究此类体质易生肿瘤。调理治疗宜调畅情志,疏通气机。Qi depression constitution is a physical state formed by long-term emotional depression and stagnation of Qi, characterized by introverted and unstable personality, melancholy and fragility, sensitivity and suspicion. People with this physical state are mostly middle-aged and young people, and more often women. They are often lonely and introverted, easily sentimental, and narrow-minded. The main disease of people with Qi depression constitution is the liver, and also affects the heart, stomach, large intestine, and small intestine. It is easy to hurt emotions and diet, and it is easy to produce Qi stagnation, such as depression, insomnia, plum pit qi, panic, etc. Modern research shows that this kind of constitution is prone to tumors. Conditioning treatment should be used to regulate emotions and dredge Qi.
多囊卵巢综合征(PCOS)是生育年龄妇女常见的一种复杂的内分泌及代谢异常所致的疾病,以慢性无排卵(排卵功能紊乱或丧失)和高雄激素血症(妇女体内男性激素产生过剩)为特征,主要临床表现为月经周期不规律、不孕、多毛和/或痤疮,是最常见的女性内分泌疾病。Polycystic ovary syndrome (PCOS) is a common disease caused by complex endocrine and metabolic abnormalities in women of childbearing age. It is characterized by chronic anovulation (ovulation dysfunction or loss) and hyperandrogenism (excess production of male hormones in women). The main clinical manifestations are irregular menstrual cycles, infertility, hirsutism and/or acne. It is the most common female endocrine disease.
中医体质穴位敷贴是将中药研末调制成药膏后贴敷在体表穴位的一种外治法,是中医从古至今常用的外治法之一。中医体质穴位贴疗法是基于中医药理论的指导下,根据“内病外治”的原则,利用相对应体质类型的中药,配以辛温、走窜、通经之药物贴敷于相关穴位,使药物透过皮肤腠理进入穴位经络,通过经络气血的运行作用,发挥药物的“归经”和功能效应,直达相关脏腑,旨在调整机体体质,增强抗病能力。本法多用气味倶厚中药结合体表经络穴位给药,通过药物经皮渗透吸收及腧穴特异性治疗发挥疗效。即药物经皮肤和粘膜的吸收,一部分直接作用于体表穴位,刺激穴位及经络;另一部分吸收进入全身血液循环达到有效血药浓度以发挥作用。TCM acupoint application is an external treatment method that grinds Chinese medicine into ointment and applies it to the acupoints on the body surface. It is one of the external treatment methods commonly used in TCM from ancient times to the present. TCM acupoint application therapy is based on the guidance of TCM theory and the principle of "external treatment of internal diseases". It uses Chinese medicine of corresponding constitution type, with pungent, warm, running and meridian-draining drugs, and applies them to relevant acupoints, so that the drugs can enter the acupoints and meridians through the skin pores, and exert the "return to meridians" and functional effects of the drugs through the running of meridian qi and blood, directly reaching the relevant internal organs, aiming to adjust the body constitution and enhance disease resistance. This method uses Chinese medicine with strong smell and combined with acupoints on the body surface to administer drugs, and exerts its efficacy through transdermal penetration and absorption of drugs and acupoint-specific treatment. That is, the drugs are absorbed through the skin and mucous membranes, part of which directly acts on the acupoints on the body surface to stimulate the acupoints and meridians; the other part is absorbed into the blood circulation of the whole body to reach an effective blood drug concentration to exert its effect.
中国专利文献CN111249420A公开了一种调治气郁体质的中药组合物及其制剂和应用。所述中药组合物的活性组分包括以下重量份的原料药:小麦150-450份、甘草40-80份、大枣80-120份、柴胡80-120份、枳壳120-180份、陈皮40-80份、青皮40-80份、香附120-180份、玫瑰花80-120份、绿萼梅80-120份、合欢花80-120份、酸枣仁70-230份、砂仁20-40份、白芍50-150份、莲子80-120份、白术80-120份、山楂80-120份、香橼80-120份、连翘80-120份、百合80-120份、桔梗80-120份、川芎80-120份、当归80-120份、谷芽80-120份、茯苓80-120份、银耳80-120份、竹茹50-150份和茯神80-120份。诸药共奏行气解郁之功,有效调治气郁体质。中国专利文献CN110038066A公开了一种治疗慢性疲劳综合征的中药组合物及其制备方法。它是由以下重量配比的原料药制备而成的制剂:黄芪15-25份,党参10-20份,白术10-20份,枸杞子6-15份,炙甘草6-15份。所述中药组合物能够有效改善慢性疲劳综合征和气虚体质,所述中药组合物可以用于制备治疗慢性疲劳综合征或气郁体质的药物。但是关于本发明一种改善气郁体质的中药组合物及其制备方法和应用目前还未见报道。Chinese patent document CN111249420A discloses a Chinese medicine composition for treating qi stagnation constitution, its preparation and application. The active components of the Chinese medicine composition include the following raw materials in parts by weight: 150-450 parts of wheat, 40-80 parts of liquorice, 80-120 parts of jujube, 80-120 parts of bupleurum, 120-180 parts of fructus aurantii, 40-80 parts of dried tangerine peel, 40-80 parts of green peel, 120-180 parts of cyperus, 80-120 parts of rose, 80-120 parts of green calyx plum, 80-120 parts of julibrissin, 70-230 parts of spinach seed, 20-20 parts of amomum villosum 40 parts, white peony root 50-150 parts, lotus seed 80-120 parts, atractylodes 80-120 parts, hawthorn 80-120 parts, citron 80-120 parts, forsythia suspensa 80-120 parts, lily 80-120 parts, platycodon 80-120 parts, chuanxiong 80-120 parts, angelica 80-120 parts, malt sprout 80-120 parts, tuckahoe 80-120 parts, tremella 80-120 parts, bamboo shavings 50-150 parts and poria 80-120 parts. All the medicines work together to promote qi and relieve depression, and effectively regulate qi stagnation constitution. Chinese patent document CN110038066A discloses a Chinese medicine composition for treating chronic fatigue syndrome and its preparation method. The preparation is prepared from the following raw materials in weight ratio: 15-25 parts of Astragalus, 10-20 parts of Codonopsis, 10-20 parts of Atractylodes, 6-15 parts of Lycium barbarum, and 6-15 parts of Radix Glycyrrhizae Preparata. The Chinese medicine composition can effectively improve chronic fatigue syndrome and qi deficiency constitution, and the Chinese medicine composition can be used to prepare medicine for treating chronic fatigue syndrome or qi stagnation constitution. However, there is no report on the Chinese medicine composition for improving qi stagnation constitution and its preparation method and application.
气虚体质(qi deficiency constitution)是指当人体脏腑功能失调,气的化生不足时,易出现气虚表现,常表现为语声低微,形体消瘦或偏胖,面色苍白,气短懒言,精神不振,体倦乏力,常自汗出,动则尤甚,舌淡红,舌边有齿痕,苔白,脉虚弱,因各种病因而发病,因心肺脾肾气虚部位不同而并见不同的症状,发病倾向:易患感冒、气虚眩晕、内脏下垂,平素抵抗力弱,妇女分娩后易患产后虚羸、产后目病等,病后康复缓慢。治疗以补气养气为总治则,还应针对脏腑辨证,分别选用补脏腑之气方药。根据气血同源理论,适当加用补血药。Qi deficiency constitution refers to the situation that when the organs of the human body are dysfunctional and the transformation of qi is insufficient, it is easy to have qi deficiency symptoms, which are often manifested as low voice, thin or overweight body, pale complexion, shortness of breath, laziness, lack of energy, fatigue, spontaneous sweating, especially when moving, pale red tongue, tooth marks on the edge of the tongue, white fur, weak pulse, and various causes of disease. Different symptoms are seen due to different parts of the heart, lung, spleen and kidney qi deficiency. The tendency of disease: easy to catch cold, qi deficiency dizziness, visceral prolapse, weak resistance, women are prone to postpartum weakness and postpartum eye disease after childbirth, and slow recovery after illness. The general principle of treatment is to replenish qi and nourish qi. It should also be based on the syndrome differentiation of the organs and select the prescriptions and medicines that replenish the qi of the organs. According to the theory of the same origin of qi and blood, blood tonic drugs should be added appropriately.
中医体质穴位贴是将中药研末调制成药膏后贴敷在体表穴位的一种外治法。中医体质穴位贴疗法是通过根据“内病外治”的原则,利用相对应体质类型的中药,配以辛温、走窜、通经之药物贴敷于相关穴位,使药物透过皮肤腠理进入穴位经络,通过经络气血的运行作用,发挥药物的“归经”和功能效应,直达相关脏腑,旨在调整机体体质,增强抗病能力。TCM acupuncture points patch is a kind of external treatment method that grinds Chinese medicine into ointment and applies it to the acupuncture points on the body surface. TCM acupuncture points patch therapy is based on the principle of "external treatment of internal diseases", using Chinese medicine corresponding to the body type, with pungent and warm, running and menstruation drugs, applied to the relevant acupuncture points, so that the drugs can penetrate the skin and enter the acupuncture points and meridians, and through the circulation of qi and blood in the meridians, the drugs' "return to the meridians" and functional effects are exerted, reaching the relevant internal organs directly, aiming to adjust the body constitution and enhance disease resistance.
中国专利文献CN107261101A公开了一种针对气虚体质按摩中药油乳,其组分按重量份包括:炒白芍12-20份、当归8-12份、炙桂枝5-13份、人参5-15份、西洋参5-13份、党参8-15份、太子参5-15份、黄芪3-15份、白术3-15份、甘草2-8份、红枣5-10份、刺五加5-12份、绞股蓝2-12份、红景天5-15份、茯苓5-15份、饴糖5-15份。所述发明以天然中草药为主要原料,经科学合理配比,补气、强身健体的功效显著,尤其是对气虚体质的人群最为显著。中国专利文献CN103768556A公开了一种调治气虚体质的中药组合物,其质量配比如下:黄芪150-300份,生晒参60-120份,西洋参60-120份,炒白术150-200份,茯苓150-300份,山药150-300份,炒白芍120-200份,炒当归120-150份,陈皮90-120份,炙桂枝90-120份,麦冬90-120份,五味子90-120份,防风90-120份,柴胡90-120份,升麻60-90份,干姜5-15份,炒薏苡仁300-500份,大枣150-300份,炙甘草60-90份,炒谷芽100-120份,炒麦芽100-120份,阿胶250-300份,龟板胶150-200份,鹿角胶100-150份。所述发明配方合理,具有补中益气、健脾补肺、消食和胃、益肾培元的作用,能有效改善甚至改变气虚体质,有效药物成分含量高、无明显毒副作用、作用药力缓和、稳定持久、服用方便、易存易携。但是关于本发明一种改善气虚体质的中药组合物及其制备方法和应用目前还未见报道。Chinese patent document CN107261101A discloses a massage Chinese medicine oil emulsion for qi deficiency constitution, and its components include by weight: 12-20 parts of stir-fried white peony root, 8-12 parts of angelica, 5-13 parts of roasted cassia twig, 5-15 parts of ginseng, 5-13 parts of American ginseng, 8-15 parts of codonopsis, 5-15 parts of pseudostellaria, 3-15 parts of astragalus, 3-15 parts of atractylodes, 2-8 parts of liquorice, 5-10 parts of red dates, 5-12 parts of acanthopanax senticosus, 2-12 parts of gynostemma pentaphyllum, 5-15 parts of rhodiola rosea, 5-15 parts of poria, and 5-15 parts of maltose. The invention uses natural Chinese herbal medicine as the main raw material, and after scientific and reasonable proportioning, it has significant effects of replenishing qi and strengthening the body, especially for people with qi deficiency constitution. Chinese patent document CN103768556A discloses a Chinese medicine composition for treating qi deficiency constitution, and its mass proportion is as follows: 150-300 parts of astragalus, 60-120 parts of raw sun-dried ginseng, 60-120 parts of American ginseng, 150-200 parts of stir-fried atractylodes, 150-300 parts of poria, 150-300 parts of yam, 120-200 parts of stir-fried white peony root, 120-150 parts of stir-fried angelica, 90-120 parts of tangerine peel, 90-120 parts of roasted cassia twig 0 parts, 90-120 parts of Radix Ophiopogonis, 90-120 parts of Fructus Schisandrae Chinensis, 90-120 parts of Saposhnikovia Divaricata, 90-120 parts of Radix Bupleuri, 60-90 parts of Cimicifuga Herba, 5-15 parts of Dried Ginger, 300-500 parts of Stir-fried Semen Coix, 150-300 parts of Jujube, 60-90 parts of Radix Glycyrrhizae Preparata, 100-120 parts of Stir-fried Malt, 250-300 parts of Ejiao, 150-200 parts of Tortoise Shell Glue, and 100-150 parts of Deer Horn Glue. The invention has a reasonable formula, has the effects of tonifying the middle qi, strengthening the spleen and lung, promoting digestion and harmonizing the stomach, and tonifying the kidney and nourishing the essence, can effectively improve or even change the constitution of qi deficiency, has a high content of effective drug ingredients, has no obvious toxic and side effects, has a mild effect, is stable and lasting, is convenient to take, and is easy to store and carry. However, there is no report on the Chinese medicine composition for improving qi deficiency constitution and its preparation method and application.
发明内容Summary of the invention
一种改善湿热体质的中药组合物及其制备方法和应用A Chinese medicine composition for improving damp-heat constitution and its preparation method and application
本发明的目的是针对现有技术中的不足,提供一种改善湿热体质的中药组合物。The purpose of the present invention is to provide a Chinese medicine composition for improving damp-heat constitution in view of the deficiencies in the prior art.
本发明的再一的目的是,提供所述中药组合物的制备方法。Another object of the present invention is to provide a method for preparing the traditional Chinese medicine composition.
本发明的另一的目的是,提供所述中药组合物的应用。Another object of the present invention is to provide an application of the traditional Chinese medicine composition.
一种改善湿热体质的中药组合物,所述的中药组合物由以下重量份的原料药制成:苍术10-20份、怀牛膝10-20份、薏苡仁10-20份、厚朴10-20份、天竺子10-20份、制胆星10-20份。A traditional Chinese medicine composition for improving damp-heat constitution is prepared from the following raw materials in parts by weight: 10-20 parts of Atractylodes lancea, 10-20 parts of Rhizoma Cyathulae, 10-20 parts of Semen Coicis, 10-20 parts of Magnolia officinalis, 10-20 parts of Fructus Tetrandrae, and 10-20 parts of processed Glehnia littoralis.
优选地,所述的中药组合物由以下重量份的原料药制成:苍术13-18份、怀牛膝13-18份、薏苡仁13-18份、厚朴13-18份、天竺子13-18份、制胆星13-18份。Preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 13-18 parts of Atractylodes lancea, 13-18 parts of Rhizoma Cyathulae, 13-18 parts of Semen Coicis, 13-18 parts of Magnolia officinalis, 13-18 parts of Fructus Tetrandrae, and 13-18 parts of processed Glehnia littoralis.
更优选地,所述的中药组合物由以下重量份的原料药制成:苍术15份、怀牛膝15份、薏苡仁15份、厚朴15份、天竺子15份、制胆星15份。More preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 15 parts of Atractylodes lancea, 15 parts of Rhizoma Cyathulae, 15 parts of Semen Coicis, 15 parts of Magnolia officinalis, 15 parts of Fructus Tetrandrae, and 15 parts of processed Glehnia littoralis.
为实现上述第二个目的,本发明采取的技术方案是:To achieve the above second purpose, the technical solution adopted by the present invention is:
如上任一所述的中药组合物的制备方法,包括以下步骤:按比例称取苍术:怀牛膝:薏苡仁:厚朴:天竺子:制胆星=1:1:1:1:1:1并打碎成粉,混合均匀。The method for preparing any of the above-mentioned traditional Chinese medicine compositions comprises the following steps: weighing Atractylodes lancea: Rhizoma Cyathulae: Semen Coix Lachryma-jobi: Cortex Magnoliae: Fructus Tetrandrae: Radix Glehniae: Radix Glehniae in the ratio of 1:1:1:1:1:1, crushing into powder, and mixing evenly.
为实现上述第三个目的,本发明采取的技术方案是:To achieve the third purpose, the technical solution adopted by the present invention is:
如上任一所述的中药组合物在制备改善的湿热体质药物中的应用。Use of any of the above-mentioned Chinese medicine compositions in the preparation of medicines for improving damp-heat constitution.
优选地,所述药物剂型为外用制剂。Preferably, the pharmaceutical dosage form is an external preparation.
更优选地,所述外用制剂的剂型为贴剂、糊剂、软膏剂、凝胶剂、涂膜剂或巴布剂。More preferably, the dosage form of the external preparation is a patch, a paste, an ointment, a gel, a film coating or a cataplasm.
一种改善湿热体质的穴位敷贴,所述的穴位敷贴由以上任一所述中药组合物混合透皮剂制成。An acupuncture point patch for improving damp-heat constitution, the acupuncture point patch is made of any of the above-mentioned traditional Chinese medicine compositions mixed with a transdermal agent.
优选地,所述透皮剂由热熔剂基质和氮酮按1000:10的比例制成。Preferably, the transdermal preparation is made of a hot melt matrix and azone in a ratio of 1000:10.
本发明优点在于:The advantages of the present invention are:
1、本发明中药组合物中所选用药物,苍术味性温,辛、苦,归脾、胃、肝经,具有燥湿健脾的功效;厚朴性温,味苦、辛,归脾、胃、肺、大肠经,具有燥湿消痰的功效;薏苡仁性凉,味甘、淡,归脾、胃、肺经,具有利水渗透湿,健脾止泻的功效;怀牛膝性微温,性平,味苦、甘、酸,归肝、肾经,具有引热下行的功效;天竺子性平,味酸、甘,归肺经,具有祛风除湿,解毒的功效;制南星性温,味苦、辛,归肺、肝经,具有燥湿化痰的功效;诸药合用,佐以姜汁,引药归经,共凑健脾燥湿、引热下行之功。1. The selected drugs in the Chinese medicine composition of the present invention are: Atractylodes macrocephala is warm in nature, pungent and bitter, and enters the spleen, stomach and liver meridians, and has the effect of drying dampness and invigorating the spleen; Magnolia officinalis is warm in nature, bitter and pungent in taste, enters the spleen, stomach, lung and large intestine meridians, and has the effect of drying dampness and eliminating phlegm; Coix seed is cool in nature, sweet and light in taste, enters the spleen, stomach and lung meridians, and has the effect of promoting diuresis, penetrating dampness, invigorating the spleen and stopping diarrhea; Achyranthes bidentata is slightly warm in nature, neutral in nature, bitter, sweet and sour in taste, enters the liver and kidney meridians, and has the effect of leading heat downward; Gardenia jasminoides is neutral in nature, sour and sweet in taste, enters the lung meridian, and has the effect of dispelling wind and dampness and detoxifying; Processed Arisaema is warm in nature, bitter and pungent in taste, enters the lung and liver meridians, and has the effect of drying dampness and resolving phlegm; all the drugs are used together, assisted by ginger juice, and the drugs are led to the meridians, so as to work together to invigorate the spleen, dry dampness and lead heat downward.
2、本发明中药组合物穴位敷贴选穴以阳陵泉、支沟、曲泉为主。曲泉有清利湿热,通调下焦的功效。支沟归属手少阳三焦经,阳陵泉归属足少阳胆经,阳陵泉、支沟泻之能和解少阳而清热化湿。诸穴相任共达清热化湿、疏肝利胆之效,从而改善湿热体质偏颇群的体质状态。2. The acupoints selected for acupoint application of the Chinese medicine composition of the present invention are mainly Yanglingquan, Zhigou and Ququan. Ququan has the effect of clearing away dampness and heat and regulating the lower part of the body. Zhigou belongs to the Shaoyang triple burner meridian of the hand, and Yanglingquan belongs to the Shaoyang gallbladder meridian of the foot. Yanglingquan and Zhigou can reconcile Shaoyang and clear away heat and dampness. The acupoints are combined to achieve the effect of clearing away heat and dampness, soothing the liver and promoting gallbladder, thereby improving the physical condition of the group with damp-heat constitution bias.
3、本发明中药组合物穴位敷贴根据“内病外治”的原则,利用相对应体质类型的中药,配以辛温、走窜、通经之药物贴敷于相关穴位,使药物透过皮肤腠理进入穴位经络,通过经络气血的运行作用,发挥药物的“归经”和功能效应,直达相关脏腑,能够调整机体体质,增强抗病能力。3. The acupuncture application of the Chinese medicine composition of the present invention is based on the principle of "external treatment of internal diseases". It uses Chinese medicine of corresponding physical type, and is combined with pungent and warm, moving and menstruation-promoting drugs to apply to relevant acupuncture points, so that the drugs can penetrate the skin pores and enter the acupuncture meridians. Through the operation of meridian qi and blood, the "channel" and functional effects of the drugs are exerted, directly reaching the relevant internal organs, which can adjust the body's physical constitution and enhance disease resistance.
一种改善气郁体质的中药组合物及其制备方法和应用A Chinese medicine composition for improving qi stagnation constitution and its preparation method and application
本发明的目的是针对现有技术中的不足,提供一种改善气郁体质的中药组合物。The purpose of the present invention is to provide a Chinese medicine composition for improving qi stagnation constitution in view of the deficiencies in the prior art.
本发明的再一的目的是,提供所述中药组合物的制备方法。Another object of the present invention is to provide a method for preparing the traditional Chinese medicine composition.
本发明的另一的目的是,提供所述中药组合物的应用。Another object of the present invention is to provide an application of the traditional Chinese medicine composition.
为实现上述目的,本发明采取的技术方案是:To achieve the above object, the technical solution adopted by the present invention is:
一种改善气郁体质的中药组合物,所述的中药组合物由以下重量份的原料药制成:柴胡10-20份、香附10-20份、枳壳10-20份、甘草5-10份、玫瑰花5-10份、绿萼梅5-10份。A traditional Chinese medicine composition for improving qi stagnation constitution is prepared from the following raw materials in parts by weight: 10-20 parts of bupleurum, 10-20 parts of cyperus rotundus, 10-20 parts of fructus aurantii, 5-10 parts of liquorice, 5-10 parts of rose, and 5-10 parts of green-calyx plum.
优选地,所述的中药组合物由以下重量份的原料药制成:柴胡12-18份、香附12-18份、枳壳12-18份、甘草6-9份、玫瑰花6-9份、绿萼梅6-9份。Preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 12-18 parts of bupleurum, 12-18 parts of cyperus rotundus, 12-18 parts of fructus aurantii, 6-9 parts of liquorice, 6-9 parts of rose, and 6-9 parts of green-calyx plum.
更优选地,所述的中药组合物由以下重量份的原料药制成:柴胡15份、香附15份、枳壳15份、甘草7.5份、玫瑰花7.5份、绿萼梅7.5份。More preferably, the Chinese medicine composition is made of the following raw materials in parts by weight: 15 parts of bupleurum, 15 parts of cyperus rotundus, 15 parts of fructus aurantii, 7.5 parts of liquorice, 7.5 parts of rose, and 7.5 parts of green-calyx plum.
为实现上述第二个目的,本发明采取的技术方案是:To achieve the above second purpose, the technical solution adopted by the present invention is:
如上任一所述的中药组合物的制备方法,包括以下步骤:按比例称取柴胡:香附:枳壳:甘草:玫瑰花:绿萼梅=1:1:1:0.5:0.5:0.5并打碎成粉,混合均匀。The method for preparing any of the above-mentioned traditional Chinese medicine compositions comprises the following steps: weighing bupleurum: cyperus rotundus: fructus aurantii: liquorice: rose: amaranth in the proportion of 1:1:1:0.5:0.5:0.5, crushing into powder, and mixing evenly.
为实现上述第三个目的,本发明采取的技术方案是:To achieve the third purpose, the technical solution adopted by the present invention is:
如上任一所述的中药组合物在制备改善气郁体质药物中的应用。Use of any of the above-mentioned traditional Chinese medicine compositions in the preparation of medicines for improving qi stagnation constitution.
优选地,所述药物剂型为外用制剂。Preferably, the pharmaceutical dosage form is an external preparation.
更优选地,所述外用制剂的剂型为贴剂、糊剂、软膏剂、凝胶剂、涂膜剂或巴布剂。More preferably, the dosage form of the external preparation is a patch, a paste, an ointment, a gel, a film coating or a cataplasm.
一种改善气郁体质的穴位敷贴,所述的穴位敷贴由以上任一所述中药组合物混合透皮剂制成。An acupuncture point patch for improving qi stagnation constitution, the acupuncture point patch is made of any of the above-mentioned traditional Chinese medicine compositions mixed with a transdermal agent.
优选地,所述透皮剂由热熔剂基质和氮酮按1000:10的比例制成。Preferably, the transdermal preparation is made of a hot melt matrix and azone in a ratio of 1000:10.
本发明优点在于:The advantages of the present invention are:
1、本发明中药组合物中所选用药物,柴胡入性微寒,味苦,归肝、胆、肺经,具有疏肝解郁的功效;香附性平,味辛、微苦、微甘,归肝、脾、三焦经,可疏肝解郁、理气宽中;枳壳味苦、微酸,性微寒,归脾、胃、肝经,具有理气宽中、行滞消胀的功效;玫瑰花味甘、微苦,性温,归肝、脾经,具有行气活血,疏肝止痛的作用;绿萼梅性平,味酸、涩,归经肝、胃、肺经,具有平肝和胃、调畅气机功效;甘草性平,味甘,归心、胃、脾、肺经,调和诸药。以辛温之生姜调和,诸药合用,共凑行气解郁之功。1. The selected drugs in the Chinese medicine composition of the present invention are: Bupleurum chinense is slightly cold in nature, bitter in taste, and enters the liver, gallbladder, and lung meridians, and has the effect of soothing the liver and relieving depression; Cyperus rotundus is flat in nature, pungent in taste, slightly bitter, and slightly sweet in taste, and enters the liver, spleen, and triple burner meridians, and can soothe the liver and relieve depression, regulate qi and relieve fullness; Fructus Aurantii Immaturus is bitter and slightly sour in taste, slightly cold in nature, and enters the spleen, stomach, and liver meridians, and has the effect of regulating qi and relieving fullness, and relieving stagnation and distension; Rose is sweet and slightly bitter in taste, warm in nature, and enters the liver and spleen meridians, and has the effect of promoting qi and activating blood circulation, soothing the liver and relieving pain; Green calyx plum is flat in nature, sour and astringent in taste, and enters the liver, stomach, and lung meridians, and has the effect of soothing the liver and stomach, and regulating qi; Licorice is flat in nature, sweet in taste, and enters the heart, stomach, spleen, and lung meridians, and harmonizes various drugs. It is harmonized with pungent and warm ginger, and various drugs are used together to work together to promote qi and relieve depression.
2、本发明中药组合物穴位敷贴选穴以膻中、肝俞为主。膻中,为气之海,理气宽胸;肝俞,为肝脏经气输注于背部的腧穴,疏肝理气。两穴合用增强调和气血之效,从而改善气郁体质偏颇人群的体质状态。2. The acupoints selected for acupoint application of the Chinese medicine composition of the present invention are mainly Tanzhong and Ganshu. Tanzhong is the sea of qi, regulating qi and widening the chest; Ganshu is the acupoint where the liver meridian qi is infused on the back, soothing the liver and regulating qi. The two acupoints are used together to enhance the effect of harmonizing qi and blood, thereby improving the physical condition of people with qi stagnation constitution bias.
3、本发明中药组合物穴位敷贴根据“内病外治”的原则,利用相对应体质类型的中药,配以辛温、走窜、通经之药物贴敷于相关穴位,使药物透过皮肤腠理进入穴位经络,通过经络气血的运行作用,发挥药物的“归经”和功能效应,直达相关脏腑,能够调整机体体质,增强抗病能力。3. The acupuncture application of the Chinese medicine composition of the present invention is based on the principle of "external treatment of internal diseases". It uses Chinese medicine of corresponding physical type, and is combined with pungent and warm, moving and menstruation-promoting drugs to apply to relevant acupuncture points, so that the drugs can penetrate the skin pores and enter the acupuncture points and meridians. Through the operation of qi and blood in the meridians, the "channel" and functional effects of the drugs are exerted, directly reaching the relevant internal organs, which can adjust the body's physical constitution and enhance disease resistance.
一种改善气虚体质的中药组合物及其制备方法和应用A Chinese medicine composition for improving qi deficiency constitution and its preparation method and application
本发明的目的是针对现有技术中的不足,提供一种改善气虚体质的中药组合物。The purpose of the present invention is to provide a Chinese medicine composition for improving qi deficiency constitution in view of the deficiencies in the prior art.
本发明的再一的目的是,提供所述中药组合物的制备方法。Another object of the present invention is to provide a method for preparing the traditional Chinese medicine composition.
本发明的另一的目的是,提供所述中药组合物的应用。Another object of the present invention is to provide an application of the traditional Chinese medicine composition.
为实现上述目的,本发明采取的技术方案是:To achieve the above object, the technical solution adopted by the present invention is:
一种改善气虚体质的中药组合物,所述的中药组合物由以下重量份的原料药制成:黄芪10-20份、炒白术10-20份、防风10-20份、陈皮5-10份、太子参10-20份、人参1-2份。A traditional Chinese medicine composition for improving qi deficiency constitution is prepared from the following raw materials in parts by weight: 10-20 parts of astragalus, 10-20 parts of stir-fried atractylodes, 10-20 parts of siler, 5-10 parts of tangerine peel, 10-20 parts of pseudoginseng, and 1-2 parts of ginseng.
优选地,所述的中药组合物由以下重量份的原料药制成:黄芪12-18份、炒白术12-18份、防风12-18份、陈皮6-9份、太子参12-18份、人参1.2-1.8份。Preferably, the Chinese medicine composition is made of the following raw materials in parts by weight: 12-18 parts of astragalus, 12-18 parts of stir-fried atractylodes, 12-18 parts of siler, 6-9 parts of tangerine peel, 12-18 parts of pseudoginseng, and 1.2-1.8 parts of ginseng.
更优选地,所述的中药组合物由以下重量份的原料药制成:黄芪15份、炒白术15份、防风15份、陈皮7.5份、太子参15份、人参1.5份。More preferably, the Chinese medicine composition is made of the following raw materials in parts by weight: 15 parts of astragalus, 15 parts of stir-fried atractylodes, 15 parts of siler, 7.5 parts of tangerine peel, 15 parts of pseudostellaria, and 1.5 parts of ginseng.
为实现上述第二个目的,本发明采取的技术方案是:To achieve the above second purpose, the technical solution adopted by the present invention is:
如上任一所述的中药组合物的制备方法,包括以下步骤:按比例称取黄芪:炒白术:防风:陈皮:太子参:人参=1:1:1:0.5:1:0.1并打碎成粉,混合均匀,再加适量姜汁调和成膏状。The method for preparing any of the above-mentioned traditional Chinese medicine compositions comprises the following steps: weighing astragalus: stir-fried atractylodes: siler: dried tangerine peel: pseudostellaria: ginseng in a ratio of 1:1:1:0.5:1:0.1 and crushing them into powder, mixing them evenly, and then adding an appropriate amount of ginger juice to blend into a paste.
为实现上述第三个目的,本发明采取的技术方案是:To achieve the third purpose, the technical solution adopted by the present invention is:
如上任一所述的中药组合物在制备改善气虚体质药物中的应用。Use of any of the above-mentioned Chinese medicine compositions in the preparation of medicines for improving qi deficiency constitution.
优选地,所述药物剂型为外用制剂。Preferably, the pharmaceutical dosage form is an external preparation.
更优选地,所述外用制剂的剂型为贴剂、糊剂、软膏剂、凝胶剂、涂膜剂或巴布剂。More preferably, the dosage form of the external preparation is a patch, a paste, an ointment, a gel, a film coating or a cataplasm.
一种改善气虚体质的穴位敷贴,所述的穴位敷贴由以上任一所述中药组合物混合透皮剂制成。An acupuncture point patch for improving qi deficiency constitution, the acupuncture point patch is made of any of the above-mentioned traditional Chinese medicine compositions mixed with a transdermal agent.
优选地,所述透皮剂由热熔剂基质和氮酮按1000:10的比例制成。Preferably, the transdermal preparation is made of a hot melt matrix and azone in a ratio of 1000:10.
本发明优点在于:The advantages of the present invention are:
1、本发明中药组合物中所选用药物,黄芪味甘,性温,归肺、脾经,具有补气固表,利尿托毒的功效;白术味苦、甘,性温,归脾、胃经,具有健脾益气,燥湿利水,止汗等功效。防风味辛、甘,性温,归膀胱、肝、脾经具有解表祛风,胜湿,止痉的功效。陈皮味苦、辛,性温,归经归肺、脾经,具有理气健脾,燥湿化痰等功效。太子参味甘、微苦,性平,归脾、肺经,具有益气健脾,生津润肺等功效。人参味甘、微苦,性平,归脾、肺、心经,可大补元气,复脉固脱,补脾益肺,生津,安神。全方共凑益气培元、补益脾肺、行气化滞之功。1. The selected drugs in the Chinese medicine composition of the present invention are astragalus, which is sweet in taste, warm in nature, and enters the lung and spleen meridians. It has the effects of invigorating qi and strengthening the exterior, diuresis and detoxification; Atractylodes macrocephala is bitter, sweet, warm in nature, and enters the spleen and stomach meridians. It has the effects of invigorating the spleen and replenishing qi, drying dampness and promoting diuresis, and stopping sweating. The flavor of the scutellaria is pungent, sweet, and warm in nature. It enters the bladder, liver, and spleen meridians and has the effects of dispelling wind, overcoming dampness, and stopping spasms. Tangerine peel is bitter, pungent, and warm in nature. It enters the lung and spleen meridians and has the effects of regulating qi and strengthening the spleen, drying dampness and resolving phlegm. Pseudostellariae is sweet, slightly bitter, and flat in nature. It enters the spleen and lung meridians and has the effects of invigorating qi and strengthening the spleen, promoting fluid and moistening the lungs. Ginseng is sweet, slightly bitter, and flat in nature. It enters the spleen, lung, and heart meridians. It can greatly replenish vital energy, restore pulse and consolidate, invigorate the spleen and lungs, promote fluid and calm the mind. The whole recipe has the functions of invigorating qi and nourishing the essence, invigorating the spleen and lungs, and promoting qi and removing stagnation.
2、本发明中药组合物穴位敷贴选穴以气海、脾俞、足三里为主,脾俞为经气输注于背部的腧穴,气海、足三里均为补气培元的要穴,《铜人腧穴针灸图经》载:“气海者,是男子生气之海也。”此穴有培补元气,益肾固精,补益回阳。《千金要方》云:“若要安,三里常不干。”三穴合用增强补气强身,延年益寿之功,从而改善气虚体质偏颇人群的体质状态。2. The acupoints selected for the acupoint application of the Chinese medicine composition of the present invention are mainly Qihai, Pishu and Zusanli. Pishu is the acupoint for infusion of meridian qi on the back. Qihai and Zusanli are both key acupoints for replenishing qi and nourishing the essence. The "Illustrated Classic of Acupoints and Acupuncture for the Bronze Man" contains: "Qihai is the sea of vitality for men." This acupoint has the functions of nourishing the vital energy, strengthening the kidney and consolidating the essence, and replenishing and restoring yang. "Qianjin Yaofang" says: "If you want to be at peace, Sanli is often not dry." The three acupoints are used together to enhance the merits of replenishing qi and strengthening the body, prolonging life, thereby improving the physical condition of people with qi deficiency constitution bias.
3、本发明中药组合物穴位敷贴根据“内病外治”的原则,利用相对应体质类型的中药,配以辛温、走窜、通经之药物贴敷于相关穴位,使药物透过皮肤腠理进入穴位经络,通过经络气血的运行作用,发挥药物的“归经”和功能效应,直达相关脏腑,能够调整机体体质,增强抗病能力。3. The acupuncture application of the Chinese medicine composition of the present invention is based on the principle of "external treatment of internal diseases". It uses Chinese medicine of corresponding physical type, and is combined with pungent and warm, moving and menstruation-promoting drugs to apply to relevant acupuncture points, so that the drugs can penetrate the skin pores and enter the acupuncture points and meridians. Through the operation of qi and blood in the meridians, the "channel" and functional effects of the drugs are exerted, directly reaching the relevant internal organs, which can adjust the body's physical constitution and enhance disease resistance.
具体实施方式DETAILED DESCRIPTION
一种改善湿热体质的中药组合物及其制备方法和应用A Chinese medicine composition for improving damp-heat constitution and its preparation method and application
实施例如下:The examples are as follows:
实施例1本发明中药组合物的制备(一)Example 1 Preparation of the Chinese medicine composition of the present invention (I)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各15份。Weigh 15 parts each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch according to the ratio of 1:1:1:1:1:1.
实施例2本发明中药组合物的制备(二)Example 2 Preparation of the Chinese medicine composition of the present invention (II)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各10份。Weigh 10 portions each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch in the ratio of 1:1:1:1:1:1.
实施例3本发明中药组合物的制备(三)Example 3 Preparation of the Chinese medicine composition of the present invention (III)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各20份。Weigh 20 portions each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch in the ratio of 1:1:1:1:1:1.
实施例4本发明中药组合物的制备(四)Example 4 Preparation of the Chinese medicine composition of the present invention (IV)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各11份。Weigh 11 parts each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch according to the ratio of 1:1:1:1:1:1.
实施例5本发明中药组合物的制备(五)Example 5 Preparation of the Chinese medicine composition of the present invention (V)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各12份。Weigh 12 portions each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch in the ratio of 1:1:1:1:1:1.
实施例6本发明中药组合物的制备(六)Example 6 Preparation of the Chinese medicine composition of the present invention (VI)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各13份。Weigh 13 parts each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch according to the ratio of 1:1:1:1:1:1.
实施例7本发明中药组合物的制备(七)Example 7 Preparation of the Chinese medicine composition of the present invention (VII)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各14份。Weigh 14 portions each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch according to the ratio of 1:1:1:1:1:1.
实施例8本发明中药组合物的制备(八)Example 8 Preparation of the Chinese medicine composition of the present invention (VIII)
按比例1:1:1:1:1:1称取原料药制南星、制半夏、延胡索、生白术、苍术、茯苓各16份。Weigh 16 portions each of the raw materials processed Arisaema, processed Pinellia, Corydalis, Raw Atractylodes, Atractylodes, and Poria in the ratio of 1:1:1:1:1:1.
实施例9本发明中药组合物的制备(九)Example 9 Preparation of the Chinese medicine composition of the present invention (IX)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各17份。Weigh 17 parts each of the raw materials Atractylodes lancea, Achyranthes bidentata, Coix seeds, Magnolia officinalis, Gardenia jasminoides, and processed Bile Starch according to the ratio of 1:1:1:1:1:1.
实施例10本发明中药组合物的制备(十)Example 10 Preparation of the Chinese medicine composition of the present invention (X)
按比例1:1:1:1:1:1称取原料药苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星各18份。Weigh 18 portions each of the raw materials Atractylodes lancea, Rhizoma Cyathulae, Semen Coicis, Magnolia officinalis, Fructus Gardeniae, and Radix Glechomae Preparata in the ratio of 1:1:1:1:1:1.
实施例11本发明中药组合物穴位敷贴的制备Example 11 Preparation of acupuncture point application of the Chinese medicine composition of the present invention
(1)实施例1-10任一所述的重量份配比称取各原料药,并打碎成粉,再混合适量姜汁和热熔胶基质调和成膏状,中药粉与热熔胶基质比例一般为1:3。(1) Weigh each raw material medicine in the weight proportion described in any one of Examples 1-10, crush it into powder, and then mix it with appropriate amount of ginger juice and hot melt adhesive matrix to form a paste. The ratio of Chinese medicine powder to hot melt adhesive matrix is generally 1:3.
(2)将上述混合物先制作成流浸膏,并用适宜的溶剂(水中加20%-25%的乙醇)提取,后蒸去部分溶剂,以将浓度调整至每1ml相当于药材1g。(2) The above mixture is first made into a fluid extract, and extracted with a suitable solvent (20%-25% ethanol in water), and then part of the solvent is evaporated to adjust the concentration to 1 ml equivalent to 1 g of medicinal material.
(3)将医用压敏热溶胶1kg,放入锅内加热至80℃左右融化,后降温至60-70℃左右时将药粉徐徐加入搅拌均匀,40℃左右时加入流浸膏、氮酮(透皮剂其中基质和氮酮的比例在1000:10左右),持续搅拌,然后摊膏,制成直径4-5cm、厚度约2-3mm的药饼。(3) Place 1 kg of medical pressure-sensitive hot melt adhesive in a pot and heat to about 80°C to melt. When the temperature drops to about 60-70°C, slowly add the drug powder and stir evenly. When the temperature is about 40°C, add the fluid extract and azone (the ratio of the base to azone in the transdermal agent is about 1000:10), continue stirring, and then spread the paste to make a drug cake with a diameter of 4-5 cm and a thickness of about 2-3 mm.
实施例12本发明中药组合物贴剂的制备Example 12 Preparation of the Chinese medicine composition patch of the present invention
(1)按照实施例1-10任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 1-10, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,除去水溶液,所得浸膏真空干燥;(2) the above-mentioned drug solution is concentrated under vacuum to remove the aqueous solution, and the obtained extract is vacuum dried;
(3)称取上述浸膏2g,加入药用甘油2-6ml,调成糊状,均匀的摊铺在固定大小的方形医用胶布上,四周边缘留出一定大小来固定胶布。(3) Weigh 2 g of the above extract, add 2-6 ml of medical glycerin, mix into a paste, and spread evenly on a square medical tape of a fixed size, leaving a certain size around the edges to fix the tape.
实施例13本发明中药组合物软膏剂的制备Example 13 Preparation of the Chinese medicine composition ointment of the present invention
(1)按照实施例1-10任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 1-10, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)在浓缩液中加入蜂蜡和黄凡士林,温火煎熬搅拌,冷却成膏状物。(3) Add beeswax and yellow vaseline to the concentrate, simmer and stir over low heat, and cool until it becomes a paste.
实施例14本发明中药组合物凝胶剂的制备Example 14 Preparation of the Chinese medicine composition gel of the present invention
(1)按照实施例1-10任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 1-10, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)将卡波姆加入甘油中研磨使其润湿,再加入少量蒸馏水研磨后,移到量杯中,另取三乙醇胺、羟苯乙酯、蒸馏水适量使其溶解,搅拌成凝胶状,再加适量蒸馏水搅匀;加入上述浓缩液,研磨均匀即得。(3) Add carbomer to glycerin and grind it to moisten it. Then add a small amount of distilled water to grind it, transfer it to a measuring cup, take appropriate amounts of triethanolamine, ethylparaben, and distilled water to dissolve them, stir them into a gel, add appropriate amount of distilled water and stir evenly; add the above concentrate and grind it evenly.
实施例15本发明中药组合物巴布剂的制备Example 15 Preparation of the Chinese medicine composition cataplasm of the present invention
(1)按照实施例1-10任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 1-10, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)在浓缩液中加入山梨醇、甘油等常规巴布剂基质,搅匀,涂布于支持层,加入保护层即得。(3) Add sorbitol, glycerol and other conventional poultice bases to the concentrate, stir well, apply to the support layer, and add a protective layer.
实施例16本发明中药组合物穴位敷贴的临床实验Example 16 Clinical Experiment on Acupoint Application of the Chinese Medicine Composition of the Present Invention
1研究对象1 Research subjects
1.1样本来源1.1 Sample Source
本实验样本来源自2020年6月至2021年3月就诊于上海中医药大学附属曙光医院门诊及住院部中符合纳入标准的中医湿热体质、痛风性关节炎患者30例,并随机分成干预组及对照组患者各15例。The samples for this experiment were derived from 30 patients with TCM damp-heat constitution and gouty arthritis who met the inclusion criteria and visited the outpatient and inpatient departments of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from June 2020 to March 2021. They were randomly divided into an intervention group and a control group with 15 patients in each group.
1.2诊断标准1.2 Diagnostic criteria
1.2.1中医湿热体质诊断标准1.2.1 Diagnostic criteria for damp-heat constitution in traditional Chinese medicine
根据2009年4月9日中国中医药出版社出版的《中医体质分类与判定》积分量表转化分结果并结合医生判断,判断受试者体质为湿热体质。According to the conversion results of the integral scale in "Classification and Determination of Constitution in Traditional Chinese Medicine" published by China Traditional Chinese Medicine Press on April 9, 2009 and combined with the doctor's judgment, the subject's constitution was judged to be damp-heat constitution.
湿热体质判定问卷:①您面部或鼻部有油腻感或者油光发亮吗?②您容易生痤疮或疮疖吗?③您感到口苦或者嘴里有异味吗?④您大便黏滞不爽、有解不尽的感觉吗?⑤您小便时尿道有发热感、尿色浓(深)吗?⑥您带下色黄(白带颜色发黄)吗?(限女性回答)⑦您阴囊部位潮湿吗?(限男性回答)Questionnaire for determining damp-heat constitution: ①Does your face or nose feel greasy or shiny? ②Do you easily get acne or boils? ③Do you feel bitter or have a bad taste in your mouth? ④Do you have sticky and uncomfortable stools or a feeling of incomplete defecation? ⑤Do you feel a heat in your urethra when you urinate, and is your urine dark (dark)? ⑥Does your vaginal discharge have a yellow color (leucorrhea is yellowish)? (Female answers only) ⑦Does your scrotum area have moisture? (Male answers only)
判定标准如下表:The judgment criteria are as follows:
表1中医体质判定标准表Table 1 Standards for determining TCM constitution
注:1.计分方法:每个条目按照“没有(或)不”“很少”“有时”“经常”“总是”分别依次计1、2、3、4、5分。2.转化分数=(各条目总分-条目数)/(条目数×4)×100;范围为0-100分。Note: 1. Scoring method: Each item is scored 1, 2, 3, 4, and 5 points respectively according to "never (or) not", "rarely", "sometimes", "often", and "always". 2. Conversion score = (total score of each item - number of items) / (number of items × 4) × 100; the range is 0-100 points.
本实验中将湿热体质转化分大于等于40分判定为湿热体质。In this experiment, a damp-heat constitution is judged as one with a damp-heat constitution conversion score of 40 or more.
1.2.2痛风性关节炎疾病诊断标准1.2.2 Diagnostic criteria for gouty arthritis
中医诊断符合《中医病证诊断疗效标准》对痛风(痹证)的规定;西医诊断符合《原发性痛风诊断和治疗指南》对痛风和痛风性关节炎的规定。The TCM diagnosis complies with the provisions of the "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes" for gout (arthritis); the Western medicine diagnosis complies with the provisions of the "Guidelines for the Diagnosis and Treatment of Primary Gout" for gout and gouty arthritis.
1.3纳入标准1.3 Inclusion criteria
1.第一诊断必须符合痛风和痛风性关节炎,无治疗禁忌症的患者;1. The first diagnosis must be consistent with gout and gouty arthritis, and the patient has no contraindications to treatment;
2.患者合并其他疾病,但在治疗期间不需特殊处理也不影响第一诊断的临床路径流程实施时,可以进入路径;2. Patients with other diseases who do not require special treatment during treatment and do not affect the implementation of the clinical pathway process of the first diagnosis can enter the pathway;
3.就诊前4周内未采用糖皮质激素、秋水仙碱或非甾体类抗炎镇痛类药物治疗;入组前均签署知情同意书。3. No glucocorticoids, colchicine or non-steroidal anti-inflammatory analgesics were used within 4 weeks before the visit; all patients signed an informed consent form before enrollment.
1.4排除标准1.4 Exclusion criteria
1.合并风湿性关节炎、系统性红斑狼疮、化脓性关节炎等可能引起关节病变的疾病患者;1. Patients with diseases that may cause joint lesions, such as rheumatoid arthritis, systemic lupus erythematosus, and suppurative arthritis;
2.合并心脑血管系统、肝肾系统及造血系统等严重原发性疾病者;2. Patients with severe primary diseases of the cardiovascular, cerebrovascular, liver, kidney and hematopoietic systems;
3.治疗依从性较差者。3. Those with poor treatment compliance.
1.5脱落标准1.5 Shedding Standard
1.治疗期间病情加重,需要特殊处理,导致治疗时间延长、费用增加;1. The condition worsens during treatment and requires special treatment, resulting in longer treatment time and increased costs;
2.出现严重并发症,退出路径;2. Severe complications and exit pathways;
3.治疗期间出现其他疾病需要治疗,退出本路径;3. If other diseases occur during treatment and require treatment, exit this path;
4.因患者及其家属意愿而影响本路径的执行,退出本路径。4. If the implementation of this pathway is affected by the wishes of the patient and his/her family, the patient will exit this pathway.
2研究方法2 Research Methods
2.1分组方案2.1 Grouping Scheme
本实验分组方案依据随机数字法进行分组。具体操作如下:借助EXCEL软件“=rand()”建立随机数字,将所得数据按从小到大排列,前15名为对照组,后15名为治疗组,共计30名患者。The experimental grouping scheme is based on the random number method. The specific operation is as follows: use the EXCEL software "=rand()" to create random numbers, and arrange the obtained data from small to large. The first 15 are the control group and the last 15 are the treatment group, with a total of 30 patients.
2.2治疗方案2.2 Treatment options
对照组治疗方案为使用依托考昔片,每次口服120mg,每日1次分为2个疗程,共60天。The treatment regimen for the control group was to use etoricoxib tablets, 120 mg orally each time, once a day, divided into 2 courses of treatment, for a total of 60 days.
治疗组治疗方案为在对照组治疗基础上使用本发明中药组合物穴位敷贴,分为2个疗程,共60天。The treatment plan for the treatment group is to use the Chinese medicine composition of the present invention for acupoint application on the basis of the treatment of the control group, which is divided into 2 courses of treatment, for a total of 60 days.
本发明中药组合物穴位敷贴:由上海中医药大学附属曙光医院治未病中心针对湿热体质的特点,结合经络、穴位、药物的特性,加以融合自主研发而成。其主要组成成分为:苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星。(比例:1:1:1:1:1:1),由山东煜和堂药业有限公司按照制作流程标准统一制作(生产批号:20191002),规格为4cm×4cm/片,每片(药芯)约0.5克。The Chinese medicine composition acupuncture patch of the present invention is independently developed by the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, based on the characteristics of damp-heat constitution, combined with the characteristics of meridians, acupuncture points, and drugs. Its main components are: Atractylodes, Rhizoma Cyathulae, Semen Coix, Magnolia officinalis, Fructus Tetraphyllae, and Radix Glechomae Preparata (ratio: 1:1:1:1:1:1), and is uniformly produced by Shandong Yuhetang Pharmaceutical Co., Ltd. in accordance with the production process standards (production batch number: 20191002), with a specification of 4cm×4cm/piece, and each piece (drug core) is about 0.5 grams.
制作流程:①将上述所需中药颗粒剂按比例1:1:1:1:1:1配比并打碎成粉,再混合热熔胶基质,中药粉与热熔胶基质比例一般为1:3。②将上述混合物先制作成流浸膏,并用适宜的溶剂(水中加20%-25%的乙醇)提取,后蒸去部分溶剂,以将浓度调整至每1ml相当于药材1g。③将医用压敏热溶胶1kg,放入锅内加热至80℃左右融化,后降温至60-70℃左右时将药粉徐徐加入搅拌均匀,40℃左右时加入流浸膏、氮酮(透皮剂其中基质和氮酮的比例在1000:10左右),持续搅拌,然后摊膏。Production process: ① Mix the required Chinese medicine granules in the ratio of 1:1:1:1:1:1 and crush them into powder, then mix with hot melt adhesive matrix. The ratio of Chinese medicine powder to hot melt adhesive matrix is generally 1:3. ② First make the above mixture into a fluid extract, and extract it with a suitable solvent (20%-25% ethanol in water), and then evaporate part of the solvent to adjust the concentration to 1g of medicinal material per 1ml. ③ Put 1kg of medical pressure-sensitive hot melt adhesive into a pot and heat it to about 80℃ to melt. After cooling to about 60-70℃, slowly add the powder and stir evenly. At about 40℃, add the fluid extract and azone (the ratio of the matrix and azone in the transdermal agent is about 1000:10), continue stirring, and then spread the paste.
使用方法:嘱患者全身沐浴或擦洗肢体后,保持皮肤温润,将本发明中药组合物穴位敷贴贴于人体阳陵泉、支沟,每次4-8小时,每一周三次。Usage: ask the patient to bathe the whole body or scrub the limbs, keep the skin warm, and apply the Chinese medicine composition of the present invention to the Yanglingquan and Zhigou acupoints of the human body for 4-8 hours each time, three times a week.
2.3中医体质评分情况2.3 TCM Constitution Scoring
比较观察两组干预对象在干预前后组内及组间各体质转化分的变化情况,其中中医气虚体质转化分为主要疗效指标。The changes of constitution transformation scores within and between the two groups of intervention subjects before and after the intervention were compared and observed, among which the TCM Qi deficiency constitution transformation score was the main efficacy indicator.
2.4不良反应记录2.4 Adverse reaction records
观察使用本发明中药组合物穴位敷贴期间是否出现不良事件或敷贴药物的不良反应(如皮肤瘙痒、皮肤红肿热痛、皮肤破溃等),如有发生及时记录发生时间及处理措施。Observe whether adverse events or adverse reactions of the application drugs (such as skin itching, skin redness, swelling, heat and pain, skin ulceration, etc.) occur during the acupoint application of the Chinese medicine composition of the present invention. If any, record the time of occurrence and treatment measures in time.
2.5临床干预疗效判定标准2.5 Criteria for determining the efficacy of clinical interventions
2.5.1中医临床干预疗效判定标准2.5.1 Criteria for determining the efficacy of TCM clinical intervention
中医临床干预疗效判定依据中医湿热体质转化分进行评判,其标准参照2017年国家药品监督管理局发布的《中医病证诊断疗效标准》相关标准运用症状积分变化进行判定。The efficacy of TCM clinical intervention is judged based on the TCM damp-heat constitution transformation score. The standard refers to the relevant standards of the "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes" issued by the State Food and Drug Administration in 2017, and is judged using changes in symptom scores.
疗效指数(n)=治疗前后的症状积分差/治疗前的症状积分×100%。Therapeutic index (n) = difference in symptom scores before and after treatment/symptom scores before treatment × 100%.
①临床痊愈:临床症状、体征消失或基本消失,证候积分减少≥95%。① Clinical cure: clinical symptoms and signs disappear or basically disappear, and the syndrome score decreases by ≥95%.
②显效:临床症状、体征消失或基本消失,证候积分减少≥70%。② Markedly effective: clinical symptoms and signs disappeared or basically disappeared, and the syndrome score decreased by ≥70%.
③有效:临床症状、体征消失或基本消失,证候积分减少≥30,但<70%。③ Effective: Clinical symptoms and signs disappeared or almost disappeared, and the syndrome score decreased by ≥30 but <70%.
④无效:临床症状、体征均无明显改善,甚或加重,证候积分减少不足30%。④ Ineffective: There is no significant improvement in clinical symptoms and signs, or they may even worsen, and the syndrome score decreases by less than 30%.
2.5.2痛风性关节炎疗效判定标准2.5.2 Criteria for determining the therapeutic effect of gouty arthritis
(一)评价标准1. Evaluation criteria
(1)显效:临床症状、阳性体征完全或基本消失,关节功能恢复正常,SUA等指标恢复至正常范围。(1) Marked effect: Clinical symptoms and positive signs completely or basically disappear, joint function returns to normal, and indicators such as SUA return to normal range.
(2)好转:临床症状、阳性体征部分消失,关节功能得到一定恢复,关节功能、SUA等指标有所改善。(2) Improvement: Clinical symptoms and positive signs partially disappear, joint function is restored to a certain extent, and indicators such as joint function and SUA are improved.
(3)无效:临床症状、体征无明显缓解,关节功能、SUA等指标检查均无明显改善,甚至出现加重。(3) Ineffectiveness: There is no significant relief of clinical symptoms and signs, and there is no significant improvement in joint function, SUA and other indicators, or even worsening.
2.5.3观察指标2.5.3 Observation indicators
比较两组患者治疗前后的临床疗效,治疗前后中医湿热体质转化评分和血尿酸(UA)、红细胞沉降率(ESR)、C反应蛋白(CRP)水平。实验室指标检查分别于用药前及用药后7d抽取痛风患者血清,各检测1次UA、ESR、CRP。The clinical efficacy, TCM damp-heat constitution transformation score, and serum uric acid (UA), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels before and after treatment were compared between the two groups. Laboratory index examination Serum was drawn from gout patients before and 7 days after medication, and UA, ESR, and CRP were tested once each.
3.结果3. Results
3.1体质转化分3.1 Physical Conversion Points
表2两组患者治疗前后中医湿热体质转化分比较Table 2 Comparison of TCM damp-heat constitution transformation scores between the two groups of patients before and after treatment
注:与治疗前比较,*P<0.05;与对照组比较,^P<0.05。Note: Compared with before treatment, *P<0.05; compared with control group, ^P<0.05.
3.2两组临床疗效比较:观察组总有效率显著高于对照组(P<0.05)。3.2 Comparison of clinical efficacy between the two groups: The total effective rate of the observation group was significantly higher than that of the control group (P < 0.05).
表3两组临床疗效比较(n)Table 3 Comparison of clinical efficacy between the two groups (n)
注:与对照组比较,△P<0.05Note: Compared with the control group, △ P<0.05
3.3两组治疗后ESR、CRP、SUA水平均显著降低(P<0.05),观察组降低程度更加明显(P<0.05)。3.3 After treatment, the levels of ESR, CRP and SUA in both groups were significantly reduced (P<0.05), and the reduction in the observation group was more obvious (P<0.05).
表4两组观察指标比较Table 4 Comparison of observation indicators between the two groups
3.4安全性指标的研究结果3.4 Research results of safety indicators
患者在治疗期间均未出现敷贴药物的不良反应(如皮肤瘙痒、皮肤红肿热痛、皮肤破溃等)。During the treatment period, no adverse reactions to the medication (such as skin itching, skin redness, swelling, heat and pain, skin ulceration, etc.) occurred in the patients.
4讨论4 Discussion
4.1湿热体质的概念及临床特征4.1 Concept and clinical characteristics of damp-heat constitution
湿热体质是由于嗜烟酒、常熬夜,滋补不当,肝郁气滞,环境因素导致肝胆、脾胃功能相对不畅通,肝胆郁结化热,脾胃积滞化湿,湿热熏蒸而形成的的一种体质状态。Damp-heat constitution is a physical condition caused by addiction to smoking and drinking, staying up late, improper nourishment, liver depression and qi stagnation, and environmental factors that lead to relatively poor liver, gallbladder, spleen and stomach functions, liver and gallbladder stagnation turning into heat, spleen and stomach stagnation turning into dampness, and damp-heat fumigation.
湿热体质会表现为面垢油光,易生痤疮,口苦口干,身重困倦,大便黏滞不畅或燥结,小便短黄,男性易阴囊潮湿,女性易带下增多,舌质偏红,苔黄腻,脉滑数。易患疮疖、黄疸、热淋、便秘、胆囊炎、口腔溃疡等病。对夏末秋初湿热气候,湿重或气温偏高环境较难适应。The damp-heat constitution will be manifested as oily face, acne, bitter and dry mouth, heavy body and drowsiness, sticky stool or dry stool, short yellow urine, wet scrotum for men, increased vaginal discharge for women, red tongue, yellow and greasy tongue coating, slippery and rapid pulse. It is easy to suffer from boils, jaundice, hot stranguria, constipation, cholecystitis, oral ulcers and other diseases. It is difficult to adapt to the damp and hot climate in late summer and early autumn, heavy humidity or high temperature environment.
4.2本发明中药组合物穴位敷贴组方分析4.2 Analysis of the formula of the Chinese medicine composition for acupoint application of the present invention
本发明中药组合物穴位敷贴是由张晓天教授针对湿热体质的特点,结合经络、穴位、药物的特性,加以融合自主研发而成。其主要组成成分为苍术、怀牛膝、薏苡仁、厚朴、天竺子、制胆星。(比例:1:1:1:1:1:1),全方共共凑健脾燥湿、引热下行之功。The Chinese medicine composition acupoint application of the present invention is independently developed by Professor Zhang Xiaotian based on the characteristics of damp-heat constitution, combined with the characteristics of meridians, acupoints and drugs. Its main components are Atractylodes, Rhizoma Cynanchum, Semen Coicis, Magnolia officinalis, Fructus Tetraphyllae, and Radix Glechomae Preparata (ratio: 1:1:1:1:1:1), and the whole formula has the functions of strengthening the spleen, drying dampness and guiding heat downward.
苍术:味性温,辛、苦,归脾、胃、肝经,具有燥湿健脾的功效;Atractylodes: warm in nature, pungent and bitter, enters the spleen, stomach and liver meridians, has the effect of drying dampness and strengthening the spleen;
厚朴:性温,味苦、辛,归脾、胃、肺、大肠经,具有燥湿消痰的功效;Magnolia officinalis: warm in nature, bitter and pungent in taste, enters the spleen, stomach, lung and large intestine meridians, and has the effect of drying dampness and eliminating phlegm;
薏苡仁:性凉,味甘、淡,归脾、胃、肺经,具有利水渗透湿,健脾止泻的功效;Coix seeds: cool in nature, sweet and light in taste, enter the spleen, stomach, and lung meridians, and have the effects of promoting diuresis, penetrating dampness, strengthening the spleen and stopping diarrhea;
怀牛膝:性微温,性平,味苦、甘、酸,归肝、肾经,具有引热下行的功效;Rhizoma Achyranthis Bidentatae: slightly warm in nature, neutral in nature, bitter, sweet, and sour in taste, enters the liver and kidney meridians, and has the effect of guiding heat downward;
天竺子:性平,味酸、甘,归肺经,具有祛风除湿,解毒的功效;Indian baicalensis: neutral in nature, sour and sweet in taste, enters the lung meridian, has the effects of dispelling wind and dampness, and detoxifying;
制南星:性温,味苦、辛,归肺、肝经,具有燥湿化痰的功效;Processed Arisaema: warm in nature, bitter and pungent in taste, enters the lung and liver meridians, has the effect of drying dampness and resolving phlegm;
4.3选穴分析4.3 Acupoint Selection Analysis
选穴以曲泉、支沟、阳陵泉为主,曲泉有清利湿热,通调下焦的功效。支沟归属手少阳三焦经,阳陵泉归属足少阳胆经,阳陵泉、支沟泻之能和解少阳而清热化湿。诸穴相任共达清热化湿、疏肝利胆之效,从而改善湿热体质偏颇群的体质状态。The acupoints selected are mainly Ququan, Zhigou and Yanglingquan. Ququan has the effect of clearing dampness and heat and regulating the lower part of the body. Zhigou belongs to the Shaoyang triple burner meridian of the hand, and Yanglingquan belongs to the Shaoyang gallbladder meridian of the foot. Yanglingquan and Zhigou can harmonize the Shaoyang meridian and clear away heat and dampness. The acupoints can achieve the effect of clearing heat and dampness, soothing the liver and promoting gallbladder function, thereby improving the physical condition of people with damp-heat constitution.
实施例17动物实验Example 17 Animal Experiment
1.材料与方法1. Materials and Methods
1.1实验材料1.1 Experimental Materials
1.1.1实验动物1.1.1 Experimental animals
SPF级Sprague-Dawley(SD)雄性小鼠40只,体质量(200±20)g,由上海斯莱克实验动物有限公司提供,饲养于恒温(22±1)℃和12∶12固定照明节律的环境下,并可自由摄取食物和水。Forty SPF Sprague-Dawley (SD) male mice weighing (200±20) g were provided by Shanghai Slake Experimental Animal Co., Ltd. They were housed in an environment with a constant temperature of (22±1)°C and a fixed lighting rhythm of 12:12, and had free access to food and water.
1.1.2实验药物本发明组:苍术15份、怀牛膝15份、薏苡仁15份、厚朴15份、天竺子15份、制胆星15份对照组1:苍术15份、怀牛膝15份、炒薏苡仁15份、砂仁15份、天竺子15份、制胆星15份对照组2:苍术15份、怀牛膝15份、薏苡仁15份、砂仁15份、天竺子15份、天竺黄15份对照组3:苍术15份、怀牛膝15份、炒薏苡仁15份、厚朴15份、天竺子15份、天竺黄15份1.1.2 Experimental drugs The present invention group: 15 parts of Atractylodes, 15 parts of Rhizoma Cyperi, 15 parts of Coix seeds, 15 parts of Magnolia bark, 15 parts of Jasmine, 15 parts of processed Gallbladder Star Control group 1: 15 parts of Atractylodes, 15 parts of Rhizoma Cyperi, 15 parts of stir-fried Coix seeds, 15 parts of Amomum, 15 parts of Jasmine, 15 parts of processed Gallbladder Star Control group 2: 15 parts of Atractylodes, 15 parts of Rhizoma Cyperi, 15 parts of Coix seeds, 15 parts of Amomum, 15 parts of Jasmine, 15 parts of Jasmine Control group 3: 15 parts of Atractylodes, 15 parts of Rhizoma Cyperi, 15 parts of stir-fried Coix seeds, 15 parts of Magnolia bark, 15 parts of Jasmine, 15 parts of Jasmine
1.2实验方法1.2 Experimental methods
1.2.1实验分组:40只小鼠依据随机数字表法分为:本发明组、对照组1、对照组2、对照组3,每组10只。1.2.1 Experimental grouping: 40 mice were divided into the following groups according to the random number table method: the present invention group, control group 1, control group 2, and control group 3, with 10 mice in each group.
1.2.2湿热体质小鼠模型制造:饲养条件为本发明组、对照组1、对照组2、对照组3小鼠予以肥甘饮食(5%猪油、3%鸡蛋黄、5%蜂蜜掺入普通饲料)及尾静脉注射大肠杆菌内毒素(2μg/kg),每周2次,连续6周,以建立湿热质大鼠模型。适应性饲养6周后用于实验。1.2.2 Preparation of damp-heat constitution mouse model: The feeding conditions were as follows: mice in the present invention group, control group 1, control group 2, and control group 3 were fed a fat and sweet diet (5% lard, 3% egg yolk, and 5% honey mixed with ordinary feed) and were injected with E. coli endotoxin (2 μg/kg) in the tail vein twice a week for 6 consecutive weeks to establish a damp-heat constitution rat model. After 6 weeks of adaptive feeding, the mice were used for experiments.
随实验进行,各组大鼠出现烦躁、不停抓挠头面部,呼吸加快、静伏不动,严重者伸颈、缩胸等症状,另有不同程度的大便黏滞或溏泄伴臭秽,肛门红肿污秽,并倦怠少动,食少饮少。本实验建立的湿热模型符合综合中医四诊信息所表达的证候表现特征,贴近人体湿热证候的整体性、表征性等特征,提示湿热证型造模成功,表明造模成功。As the experiment progressed, rats in each group showed symptoms such as irritability, scratching their heads and faces constantly, rapid breathing, and immobility. In severe cases, the rats stretched their necks and shrank their chests. In addition, the rats had sticky or loose stools with foul odors to varying degrees, red and swollen anuses, and fatigue, less movement, and less food and drink. The damp-heat model established in this experiment conforms to the syndrome manifestation characteristics expressed by the comprehensive information of the four diagnostic methods of traditional Chinese medicine, and is close to the overall and representative characteristics of the damp-heat syndrome in the human body, indicating that the damp-heat syndrome model was successfully established.
1.2.3给药方法:1.2.3 Method of administration:
贴敷本发明组、贴敷对照组1、贴敷对照组2、贴敷对照组3:Patching group of the present invention, patch control group 1, patch control group 2, patch control group 3:
贴敷本发明组:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷本发明组(苍术15份、怀牛膝15份、薏苡仁15份、厚朴15份、天竺子15份、制胆星15份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.5克)贴敷8h后取掉,每日1次,共贴敷20次。The patching group of the present invention: the back of the mouse was depilated with 8% Na 2 S, the area was about 4cm×4cm, and after local disinfection with 75% alcohol, the patching group of the present invention (15 parts of Atractylodes, 15 parts of Rhizoma Achyranthis Bidentatae, 15 parts of Semen Coicis, 15 parts of Magnolia officinalis, 15 parts of Fructus Tetrandrae, 15 parts of Processed Bile Starch) was fixed on the depilated area (Tanzhong, Ganshu). Then gently press twice, and then wrap the chest and back with a self-adhesive tape to fix it. (Each piece (drug core) is about 0.5 grams) After 8 hours of application, remove it, once a day, for a total of 20 times.
贴敷对照组1:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷对照组1(苍术15份、怀牛膝15份、炒薏苡仁15份、砂仁15份、天竺子15份、制胆星15份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.3克)贴敷8h后取掉,每日1次,共贴敷20次。Patching control group 1: Depilate the back of the mouse with 8% Na 2 S, the area is about 4cm×4cm, and after local disinfection with 75% alcohol, apply the patch control group 1 (15 parts of Atractylodes, 15 parts of Rhizoma Coix, 15 parts of Amomum, 15 parts of Fructus Tetraphyllae, 15 parts of Radix Glechomae Preparata, 15 parts of Radix Glechomae Preparata) to the depilated area (Tanzhong, Ganshu). Then press gently twice, and then wrap the chest and back with adhesive tape to fix. (Each piece (drug core) is about 0.3 grams) Remove it after 8 hours of application, once a day, a total of 20 times.
贴敷对照组2:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷对照组2(苍术15份、怀牛膝15份、薏苡仁15份、砂仁15份、天竺子15份、天竺黄15份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.1克)贴敷8h后取掉,每日1次,共贴敷20次。Patching control group 2: Depilate the back of the mouse with 8% Na 2 S, the area is about 4cm×4cm, and after local disinfection with 75% alcohol, apply the patch control group 2 (15 parts of Atractylodes, 15 parts of Rhizoma Achyranthis Bidentatae, 15 parts of Semen Coicis, 15 parts of Fructus Amomi, 15 parts of Fructus Dioscoreae, 15 parts of Fructus Dioscoreae) to the depilated area (Tanzhong, Ganshu). Then press gently twice, and then wrap the chest and back with adhesive tape to fix. (Each piece (core) is about 0.1g) Remove it after 8 hours of application, once a day, a total of 20 times.
贴敷对照组3:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷对照组3(苍术15份、怀牛膝15份、炒薏苡仁15份、厚朴15份、天竺子15份、天竺黄15份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.3克)贴敷8h后取掉,每日1次,共贴敷20次。螺内酯7mg/kg,连续灌胃30天。Patching control group 3: The back of the mouse was depilated with 8% Na 2 S, the area was about 4cm×4cm, and after local disinfection with 75% alcohol, the patch control group 3 (15 parts of Atractylodes, 15 parts of Rhizoma Coix, 15 parts of Magnolia officinalis, 15 parts of Rhizoma Dioscoreae, 15 parts of Rhizoma Dioscoreae) was fixed on the depilated area (Tanzhong, Ganshu). Then gently press twice, and then wrap the chest and back with a self-adhesive tape to fix it. (Each piece (drug core) is about 0.3 grams) After 8 hours of application, remove it, once a day, for a total of 20 times. Spironolactone 7mg/kg, continuous gavage for 30 days.
1.2.4观察检测指标1.2.4 Observation and testing indicators
干预前后小鼠体重变化及血脂变化。Changes in body weight and blood lipids of mice before and after intervention.
1.2.5统计学处理1.2.5 Statistical analysis
采用SPSS10.0软件,进行单因素方差分析。SPSS10.0 software was used for one-way analysis of variance.
2.结果2. Results
表5不同贴对小鼠体重的影响(x±s,g)Table 5 Effects of different patches on the body weight of mice (x±s, g)
*p<0.05与对照组1相比,**p<0.01与对照组2相比。与对照组3比较,*p<0.01。 * p<0.05 compared with control group 1, ** p<0.01 compared with control group 2. Compared with control group 3, * p<0.01.
表6不同贴对小鼠血脂的影响(x±s,mmol/L)Table 6 Effects of different patches on blood lipids in mice (x±s, mmol/L)
*p<0.05与对照组1相比,**p<0.01与对照组2相比。与对照组3比较,*p<0.01. * p<0.05 compared with control group 1, ** p<0.01 compared with control group 2. * p<0.01 compared with control group 3.
讨论discuss
本发明选择“环境+饮食+诱因+生物感染因子”复制湿热证型模型,观察对小鼠湿热体质的改善作用。饲喂高脂饲料6周,实验结束后检测各组小鼠血清中的CHOL,LDL-C,HDL-C含量,发现在高脂饮食下,模型组小鼠血清中CHOL,LDL-C水平明显升高,HDL-C水平明显降低,出现脂质代谢紊乱。由此验证饮食失节是造成湿热证的关键因素之一。The present invention selects "environment + diet + inducement + biological infection factor" to replicate the damp-heat syndrome model and observe the improvement effect on the damp-heat constitution of mice. After feeding a high-fat diet for 6 weeks, the CHOL, LDL-C, and HDL-C levels in the serum of each group of mice were detected after the experiment. It was found that under a high-fat diet, the CHOL and LDL-C levels in the serum of the model group mice were significantly increased, and the HDL-C level was significantly reduced, and lipid metabolism disorders occurred. This verifies that dietary disorder is one of the key factors causing damp-heat syndrome.
实施例中贴本发明组干预小鼠前后体重增长程度小于其他组,且有统计学差异。而本发明组贴敷干预小鼠相较于对照组1、2、3CHOL,LDL-C水平明显降低,HDL-C水平升高,且具有统计学意义。本实验结果表明:湿热贴具有一定调脂样作用。In the embodiment, the weight gain of mice in the group treated with the present invention before and after the intervention was less than that in other groups, and there was a statistical difference. Compared with the control groups 1, 2, and 3CHOL, the LDL-C level of mice in the group treated with the present invention was significantly reduced, and the HDL-C level was increased, and there was statistical significance. The experimental results show that the moist heat patch has a certain lipid-regulating effect.
一种改善气郁体质的中药组合物及其制备方法和应用A Chinese medicine composition for improving qi stagnation constitution and its preparation method and application
实施例18本发明中药组合物的制备(一)Example 18 Preparation of the Chinese medicine composition of the present invention (I)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡15份、香附15份、枳壳15份、甘草7.5份、玫瑰花7.5份、绿萼梅7.5份。Weigh 15 parts of the raw materials Bupleurum, 15 parts of Cyperus, 15 parts of Fructus Aurantii Immaturus, 7.5 parts of Licorice, 7.5 parts of Rose, and 7.5 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例19本发明中药组合物的制备(二)Example 19 Preparation of the Chinese medicine composition of the present invention (II)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡10份、香附10份、枳壳10份、甘草5份、玫瑰花5份、绿萼梅5份。Weigh 10 parts of the raw materials Bupleurum, 10 parts of Cyperus, 10 parts of Fructus Aurantii Immaturus, 5 parts of Licorice, 5 parts of Rose, and 5 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例20本发明中药组合物的制备(三)Example 20 Preparation of the Chinese medicine composition of the present invention (III)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡20份、香附20份、枳壳20份、甘草10份、玫瑰花10份、绿萼梅10份。Weigh 20 parts of the raw materials Bupleurum, 20 parts of Cyperus, 20 parts of Fructus Aurantii Immaturus, 10 parts of Licorice, 10 parts of Rose, and 10 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例21本发明中药组合物的制备(四)Example 21 Preparation of the Chinese medicine composition of the present invention (IV)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡12份、香附12份、枳壳12份、甘草6份、玫瑰花6份、绿萼梅6份。Weigh 12 parts of the raw materials Bupleurum, 12 parts of Cyperus, 12 parts of Fructus Aurantii Immaturus, 6 parts of Licorice, 6 parts of Rose, and 6 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例22本发明中药组合物的制备(五)Example 22 Preparation of the Chinese medicine composition of the present invention (V)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡18份、香附18份、枳壳18份、甘草9份、玫瑰花9份、绿萼梅9份。Weigh 18 parts of the raw materials Bupleurum, 18 parts of Cyperus, 18 parts of Fructus Aurantii Immaturus, 9 parts of Licorice, 9 parts of Rose, and 9 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例23本发明中药组合物的制备(六)Example 23 Preparation of the Chinese medicine composition of the present invention (VI)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡11份、香附11份、枳壳11份、甘草5.5份、玫瑰花5.5份、绿萼梅5.5份。Weigh 11 parts of the raw materials Bupleurum, 11 parts of Cyperus rotundus, 11 parts of Fructus Aurantii Immaturus, 5.5 parts of Licorice, 5.5 parts of Rose, and 5.5 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例24本发明中药组合物的制备(七)Example 24 Preparation of the Chinese medicine composition of the present invention (VII)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡13份、香附13份、枳壳13份、甘草6.5份、玫瑰花6.5份、绿萼梅6.5份。Weigh 13 parts of the raw materials Bupleurum, 13 parts of Cyperus, 13 parts of Fructus Aurantii Immaturus, 6.5 parts of Licorice, 6.5 parts of Rose, and 6.5 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例25本发明中药组合物的制备(八)Example 25 Preparation of the Chinese medicine composition of the present invention (VIII)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡14份、香附14份、枳壳14份、甘草7份、玫瑰花7份、绿萼梅7份。Weigh 14 parts of the raw materials Bupleurum, 14 parts of Cyperus, 14 parts of Fructus Aurantii Immaturus, 7 parts of Licorice, 7 parts of Rose, and 7 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例26本发明中药组合物的制备(九)Example 26 Preparation of the Chinese medicine composition of the present invention (IX)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡16份、香附16份、枳壳16份、甘草8份、玫瑰花8份、绿萼梅8份。Weigh 16 parts of the raw materials Bupleurum, 16 parts of Cyperus, 16 parts of Fructus Aurantii Immaturus, 8 parts of Licorice, 8 parts of Rose, and 8 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例27本发明中药组合物的制备(十)Example 27 Preparation of the Chinese medicine composition of the present invention (X)
按比例1:1:1:0.5:0.5:0.5称取原料药柴胡17份、香附17份、枳壳17份、甘草8.5份、玫瑰花8.5份、绿萼梅8.5份。Weigh 17 parts of the raw materials Bupleurum, 17 parts of Cyperus, 17 parts of Fructus Aurantii Immaturus, 8.5 parts of Licorice, 8.5 parts of Rose, and 8.5 parts of Prunus mume according to the ratio of 1:1:1:0.5:0.5:0.5.
实施例28本发明中药组合物穴位敷贴的制备Example 28 Preparation of acupuncture point application of the Chinese medicine composition of the present invention
(1)实施例18-27任一所述的重量份配比称取各原料药,并打碎成粉,再混合适量姜汁和热熔胶基质调和成膏状,中药粉与热熔胶基质比例一般为1:3。(1) Weigh each raw material medicine in the weight proportion described in any one of Examples 18-27, crush it into powder, and then mix it with appropriate amount of ginger juice and hot melt adhesive matrix to form a paste. The ratio of Chinese medicine powder to hot melt adhesive matrix is generally 1:3.
(2)将上述混合物先制作成流浸膏,并用适宜的溶剂(水中加20%-25%的乙醇)提取,后蒸去部分溶剂,以将浓度调整至每1ml相当于药材1g。(2) The above mixture is first made into a fluid extract, and extracted with a suitable solvent (20%-25% ethanol in water), and then part of the solvent is evaporated to adjust the concentration to 1 ml equivalent to 1 g of medicinal material.
(3)将医用压敏热溶胶1kg,放入锅内加热至80℃左右融化,后降温至60-70℃左右时将药粉徐徐加入搅拌均匀,40℃左右时加入流浸膏、氮酮(透皮剂其中基质和氮酮的比例在1000:10左右),持续搅拌,然后摊膏,制成直径4-5cm、厚度约2-3mm的药饼。(3) Place 1 kg of medical pressure-sensitive hot melt adhesive in a pot and heat to about 80°C to melt. When the temperature drops to about 60-70°C, slowly add the drug powder and stir evenly. When the temperature is about 40°C, add the fluid extract and azone (the ratio of the base to azone in the transdermal agent is about 1000:10), continue stirring, and then spread the paste to make a drug cake with a diameter of 4-5 cm and a thickness of about 2-3 mm.
实施例29本发明中药组合物贴剂的制备Example 29 Preparation of the Chinese medicine composition patch of the present invention
(1)按照实施例18-27任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 18-27, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,除去水溶液,所得浸膏真空干燥;(2) the above-mentioned drug solution is concentrated under vacuum to remove the aqueous solution, and the obtained extract is vacuum dried;
(3)称取上述浸膏2g,加入药用甘油2-6ml,调成糊状,均匀的摊铺在固定大小的方形医用胶布上,四周边缘留出一定大小来固定胶布。(3) Weigh 2 g of the above extract, add 2-6 ml of medical glycerin, mix into a paste, and spread evenly on a square medical tape of a fixed size, leaving a certain size around the edges to fix the tape.
实施例30本发明中药组合物软膏剂的制备Example 30 Preparation of the Chinese medicine composition ointment of the present invention
(1)按照实施例18-27任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 18-27, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) concentrating the above-mentioned drug solution under vacuum to obtain a drug solution concentrate;
(3)在浓缩液中加入蜂蜡和黄凡士林,温火煎熬搅拌,冷却成膏状物。(3) Add beeswax and yellow vaseline to the concentrate, simmer over low heat and stir, then cool to form a paste.
实施例31本发明中药组合物凝胶剂的制备Example 31 Preparation of the Chinese medicine composition gel of the present invention
(1)按照实施例18-27任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 18-27, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) concentrating the above-mentioned drug solution under vacuum to obtain a drug solution concentrate;
(3)将卡波姆加入甘油中研磨使其润湿,再加入少量蒸馏水研磨后,移到量杯中,另取三乙醇胺、羟苯乙酯、蒸馏水适量使其溶解,搅拌成凝胶状,再加适量蒸馏水搅匀;加入上述浓缩液,研磨均匀即得。(3) Add carbomer to glycerin and grind it to moisten it. Then add a small amount of distilled water to grind it, transfer it to a measuring cup, take appropriate amounts of triethanolamine, ethylparaben, and distilled water to dissolve them, stir them into a gel, add appropriate amount of distilled water and stir evenly; add the above concentrate and grind evenly to obtain the product.
实施例32本发明中药组合物巴布剂的制备Example 32 Preparation of the Chinese medicine composition cataplasm of the present invention
(1)按照实施例18-27任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 18-27, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)在浓缩液中加入山梨醇、甘油等常规巴布剂基质,搅匀,涂布于支持层,加入保护层即得。(3) Add sorbitol, glycerol and other conventional poultice bases to the concentrate, stir well, apply to the support layer, and add a protective layer.
实施例33本发明中药组合物穴位敷贴的临床实验Example 33 Clinical Experiment on Acupoint Application of the Chinese Medicine Composition of the Present Invention
1研究对象1 Research subjects
1.1样本来源1.1 Sample Source
将2020年6月至2021年3月上海中医药大学附属曙光医院门诊及住院治疗的功能性便秘(气秘型)患者70例随机分为治疗组和对照组各35例。治疗组随访依从性差脱落1例,完成研究34例,其中男16例,女18例;年龄22~70岁,平均59岁;其中3人外用活血止痛膏皮肤过敏出现皮疹,改为纱布外敷,皮疹好转,完成研究。对照组随访脱落2例,完成研究33例;其中男16例,女17例;年龄25~70岁,平均61岁。2组患者基线资料比较差异无统计学意义(P>0.05),具有可比性。A total of 70 patients with functional constipation (qi constipation type) who were treated in the outpatient and inpatient clinics of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from June 2020 to March 2021 were randomly divided into a treatment group and a control group with 35 cases in each group. One patient in the treatment group dropped out due to poor follow-up compliance, and 34 patients completed the study, including 16 males and 18 females, aged 22 to 70 years old, with an average age of 59 years old; 3 of them had skin allergies to external application of Huoxue Zhitong ointment and developed rashes, which were changed to gauze external application, and the rashes improved and the study was completed. Two patients dropped out of the control group follow-up, and 33 patients completed the study, including 16 males and 17 females, aged 25 to 70 years old, with an average age of 61 years old. There was no statistically significant difference in the baseline data of the two groups of patients (P>0.05), and they were comparable.
1.2诊断标准1.2 Diagnostic criteria
1.2.1中医气郁体质诊断标准1.2.1 Diagnostic criteria for qi stagnation constitution in traditional Chinese medicine
根据2009年4月9日中国中医药出版社出版的《中医体质分类与判定》积分量表转化分结果并结合医生判断,判断受试者体质为气郁体质。According to the conversion results of the integral scale in "Classification and Determination of Constitution in Traditional Chinese Medicine" published by China Traditional Chinese Medicine Press on April 9, 2009 and combined with the doctor's judgment, the subject's constitution was judged to be Qi Yu constitution.
气郁体质判定问卷:①您感到闷闷不乐、情绪低落吗?②您感容易精神紧张,焦虑不安吗?③您多愁善感、感情脆弱吗?④您容易害怕或受到惊吓吗?⑤您肋部或乳房胀痛吗?⑥您无缘无故叹气吗?⑦您咽喉部有异物感,且吐之不出、咽之不下吗?Questionnaire for determining qi stagnation constitution: ① Do you feel depressed and down? ② Do you feel nervous and anxious? ③ Are you sentimental and emotionally fragile? ④ Are you easily afraid or frightened? ⑤ Do you have rib or breast pain? ⑥ Do you sigh for no reason? ⑦ Do you feel a foreign body in your throat and can't spit it out or swallow it?
判定标准如下表:The judgment criteria are as follows:
表7中医体质判定标准表Table 7 Standards for determining TCM constitution
注:1.计分方法:每个条目按照“没有(或)不”“很少”“有时”“经常”“总是”分别依次计1、2、3、4、5分。2.转化分数=(各条目总分-条目数)/(条目数×4)×100;范围为0-100分。Note: 1. Scoring method: Each item is scored 1, 2, 3, 4, and 5 points respectively according to "never (or) not", "rarely", "sometimes", "often", and "always". 2. Conversion score = (total score of each item - number of items) / (number of items × 4) × 100; the range is 0-100 points.
本实验中将气郁体质转化分大于等于40分判定为气郁体质。In this experiment, people with a conversion score of 40 or more were judged as having a Qi-Stagnation Constitution.
1.2.2功能性便秘疾病诊断标准1.2.2 Diagnostic criteria for functional constipation
(一)疾病诊断1. Disease diagnosis
1.中医诊断1. Traditional Chinese Medicine Diagnosis
参照《中华人民共和国国家标准·中医临床诊疗术语证候部分》、《中医内科学》有关内容制定。It is formulated with reference to the relevant contents of "National Standard of the People's Republic of China - TCM Clinical Diagnosis and Treatment Terminology - Syndrome" and "Traditional Chinese Medicine Internal Medicine".
2.西医诊断2. Western medicine diagnosis
参照功能性便秘的罗马Ⅲ诊断标准。Refer to the Rome III diagnostic criteria for functional constipation.
1.3纳入标准1.3 Inclusion criteria
3.1)符合慢性功能性便秘的西医诊断标准者;3.1) Those who meet the Western medical diagnostic criteria for chronic functional constipation;
2)符合气秘中医辨证诊断者;2) Those who meet the TCM diagnosis of Qi constipation;
3)年龄18~70岁者;3) Aged 18 to 70;
4)受试者知情,且自愿签署知情同意书者。4) The subjects are aware of the study and voluntarily sign the informed consent.
1.4脱落标准1.4 Shedding Standard
1.治疗期间病情加重,需要特殊处理,导致治疗时间延长、费用增加;1. The condition worsens during treatment and requires special treatment, resulting in longer treatment time and increased costs;
2.出现严重并发症,退出路径;2. Severe complications and exit pathways;
3.治疗期间出现其他疾病需要治疗,退出本路径;3. If other diseases occur during treatment and require treatment, exit this path;
4.因患者及其家属意愿而影响本路径的执行,退出本路径。4. If the implementation of this pathway is affected by the wishes of the patient and his/her family, the patient will exit this pathway.
2研究方法2 Research Methods
2.1分组方案2.1 Grouping Scheme
本实验分组方案依据随机数字法进行分组。具体操作如下:借助EXCEL软件“=rand()”建立随机数字,将所得数据按从小到大排列,前35名为对照组,后35名为治疗组,共计70名患者。The experimental grouping scheme is based on the random number method. The specific operation is as follows: use the EXCEL software "=rand()" to create random numbers, and arrange the obtained data from small to large. The first 35 are the control group and the last 35 are the treatment group, with a total of 70 patients.
2.2治疗方案2.2 Treatment options
对照组治疗方案为给予四磨汤口服液(湖南汉森制药股份有限公司,批号:1610103,规格:10m L/支)口服,每次2支(20m L),3次/d。The treatment plan for the control group was to give Simotang oral liquid (Hunan Hansen Pharmaceutical Co., Ltd., batch number: 1610103, specification: 10 mL/vial) orally, 2 vials (20 mL) each time, 3 times/d.
治疗组治疗方案为使用本发明中药组合物穴位敷贴,分为2个疗程,共60天。The treatment plan for the treatment group is to use the Chinese medicine composition of the present invention for acupoint application, which is divided into 2 courses of treatment, a total of 60 days.
本发明中药组合物穴位敷贴:由上海中医药大学附属曙光医院治未病中心针对气虚体质的特点,结合经络、穴位、药物的特性,加以融合自主研发而成。其主要组成成分为柴胡、香附、枳壳、甘草、玫瑰花、绿萼梅(比例:1:1:1:0.5:0.5:0.5),由山东煜和堂药业有限公司按照制作流程标准统一制作(生产批号:20191002),规格为4cm×4cm/片,每片(药芯)约0.5克。The Chinese medicine composition acupuncture patch of the present invention is independently developed by the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, based on the characteristics of qi deficiency constitution, combined with the characteristics of meridians, acupuncture points, and drugs. Its main components are bupleurum, cyperus, fructus aurantii, licorice, rose, and green calyx plum (ratio: 1:1:1:0.5:0.5:0.5), and it is uniformly produced by Shandong Yuhetang Pharmaceutical Co., Ltd. according to the production process standards (production batch number: 20191002), with a specification of 4cm×4cm/piece, and each piece (drug core) is about 0.5 grams.
制作流程:①将上述所需中药颗粒剂按比例1:1:1:0.5:0.5:0.5配比并打碎成粉,再混合热熔胶基质,中药粉与热熔胶基质比例一般为1:3。②将上述混合物先制作成流浸膏,并用适宜的溶剂(水中加20%-25%的乙醇)提取,后蒸去部分溶剂,以将浓度调整至每1ml相当于药材1g。③将医用压敏热溶胶1kg,放入锅内加热至80℃左右融化,后降温至60-70℃左右时将药粉徐徐加入搅拌均匀,40℃左右时加入流浸膏、氮酮(透皮剂其中基质和氮酮的比例在1000:10左右),持续搅拌,然后摊膏。Production process: ① Mix the required Chinese medicine granules in the ratio of 1:1:1:0.5:0.5:0.5 and crush them into powder, then mix with hot melt adhesive matrix. The ratio of Chinese medicine powder to hot melt adhesive matrix is generally 1:3. ② First make the above mixture into a fluid extract, and extract it with a suitable solvent (20%-25% ethanol in water), and then evaporate part of the solvent to adjust the concentration to 1g of medicinal material per 1ml. ③ Put 1kg of medical pressure-sensitive hot melt adhesive into a pot and heat it to about 80℃ to melt. After cooling to about 60-70℃, slowly add the powder and stir evenly. At about 40℃, add the fluid extract and azone (the ratio of the matrix and azone in the transdermal agent is about 1000:10), continue stirring, and then spread the paste.
使用方法:嘱患者全身沐浴或擦洗肢体后,保持皮肤温润,将本发明中药组合物穴位敷贴贴于人体膻中、肝俞,每次4-8小时,每一周三次。Usage: ask the patient to bathe the whole body or scrub the limbs, keep the skin warm, and apply the Chinese medicine composition of the present invention to the Tanzhong and Ganshu points of the human body for 4-8 hours each time, three times a week.
2.3中医体质评分情况2.3 TCM Constitution Scoring
比较观察两组干预对象在干预前后组内及组间各体质转化分的变化情况,其中中医气虚体质转化分为主要疗效指标。The changes of constitution transformation scores within and between the two groups of intervention subjects before and after the intervention were compared and observed, among which the TCM Qi deficiency constitution transformation score was the main efficacy indicator.
2.4不良反应记录2.4 Adverse reaction records
观察使用本发明中药组合物穴位敷贴期间是否出现不良事件或敷贴药物的不良反应(如皮肤瘙痒、皮肤红肿热痛、皮肤破溃等),如有发生及时记录发生时间及处理措施。Observe whether adverse events or adverse reactions of the application drugs (such as skin itching, skin redness, swelling, heat and pain, skin ulceration, etc.) occur during the acupoint application of the Chinese medicine composition of the present invention. If any, record the time of occurrence and treatment measures in time.
2.5临床干预疗效判定标准2.5 Criteria for determining the efficacy of clinical interventions
主症:首次排便时间、排便间隔时间、每次排便时间及便质、便感按等级记分(轻=0分,中=2分,重=4分);兼证:腹胀、腹痛、肛裂便血、努争汗出、食欲不振出现1个症状为0.5分,没有为0分。Main symptoms: time of first bowel movement, interval between bowel movements, duration of each bowel movement, stool quality, and stool sensation are scored according to levels (mild = 0 points, moderate = 2 points, severe = 4 points); Concomitant symptoms: abdominal distension, abdominal pain, anal fissure, bloody stool, sweating due to straining, loss of appetite. The presence of any one symptom is 0.5 points, and none is 0 points.
2.6疗效标准2.6 Efficacy criteria
痊愈:大便正常,其他症状全部消失。显效:便秘明显改善,间隔时间及便质接近正常,或大便稍干而排便间隔时间在72小时以内,其他症状大部分消失,且积分减少2/3;有效:排便间隔时间缩短1天,或便质干结改善,其他症状均有好转,且积分减少l/3,而不足2/3;无效:便秘及其他症状均无改善或积分值减少不足1/3者。Cured: normal bowel movement, all other symptoms disappear. Remarkable effect: constipation is significantly improved, the interval time and stool quality are close to normal, or the stool is slightly dry and the interval time between bowel movements is within 72 hours, most of other symptoms disappear, and the score is reduced by 2/3; Effective: the interval time between bowel movements is shortened by 1 day, or the dry stool quality is improved, other symptoms are improved, and the score is reduced by 1/3, but less than 2/3; Ineffective: constipation and other symptoms are not improved or the score is reduced by less than 1/3.
2.7安全性评价2.7 Safety evaluation
观察治疗前后2组患者心电图及血、便常规与潜血、肝功能、肾功能。The electrocardiogram, routine blood and stool tests, occult blood, liver function and kidney function of the two groups of patients were observed before and after treatment.
2.8统计学方法2.8 Statistical methods
使用SPSS24.0统计软件进行统计。如果数据满足正态分布,用均数±标准差来进行描述。比较两组数据,符合正态分布,用独立样本t检验;比较干预前后数据,符合正态性,采用配对t检验;计数资料采用χ2检验;若数据不符合正态分布、或者数据为等级资料,则使用秩和检验。P<0.05为有统计学意义。SPSS 24.0 statistical software was used for statistics. If the data met the normal distribution, the mean ± standard deviation was used. To describe. To compare the two groups of data, if they were in accordance with normal distribution, the independent sample t test was used; to compare the data before and after the intervention, if they were in accordance with normality, the paired t test was used; the chi-square test was used for count data; if the data did not conform to normal distribution or the data were rank data, the rank sum test was used. P < 0.05 was considered statistically significant.
3结果3 Results
3.1临床疗效3.1 Clinical efficacy
两组临床疗效比较差异有统计学意义(Z=-4.425,P<0.01),治疗组的痊愈、显效、总有效率均高于对照组,治疗组临床疗效较对照组明显,见表8。There was a statistically significant difference in clinical efficacy between the two groups (Z=-4.425, P<0.01). The cure, marked effect and total effective rates of the treatment group were all higher than those of the control group. The clinical efficacy of the treatment group was more obvious than that of the control group, as shown in Table 8.
表8两组临床疗效比较Table 8 Comparison of clinical efficacy between the two groups
3.2证候积分3.2 Syndrome score
两组患者治疗后证候积分较治疗前改善,差异均有统计学意义(P<0.01);治疗后两组间比较差异有统计学意义(P<0.05),治疗组在改善证候积分方面较对照组明显,见表9。After treatment, the symptom scores of the two groups of patients were improved compared with those before treatment, and the differences were statistically significant (P<0.01); after treatment, the difference between the two groups was statistically significant (P<0.05), and the treatment group was more obvious in improving the symptom scores than the control group, as shown in Table 9.
表9两组证候积分比较 Table 9 Comparison of syndrome scores between the two groups
3.3体质转化分3.3 Physical Conversion Points
两组患者治疗后中医气郁体质转化分较治疗前改善,差异均有统计学意义(P<0.01);治疗后2组间比较差异有统计学意义(P<0.05),治疗组在改善中医气郁体质转化分明显,见表10。After treatment, the TCM Qi-stagnation constitution conversion scores of the two groups of patients were improved compared with those before treatment, and the differences were statistically significant (P<0.01); the difference between the two groups after treatment was statistically significant (P<0.05), and the treatment group had a significant improvement in the TCM Qi-stagnation constitution conversion score, as shown in Table 10.
表10两组患者治疗前后中医气郁体质转化分比较Table 10 Comparison of TCM Qi-stagnation Constitution Transformation Score between the Two Groups of Patients Before and After Treatment
4讨论4 Discussion
4.1气郁体质的概念及临床特征4.1 Concept and clinical characteristics of Qi stagnation constitution
气郁体质是由于长期情志不畅、气机郁滞而形成的以性格内向不稳定、忧郁脆弱、敏感多疑为主要表现的体质状态。处于这种体质状态者,多见于中青年,以女性多见,性格多孤僻内向,易多愁善感,气量较狭小。气郁体质者的发病以肝为主,兼及心、胃、大肠、小肠。易伤情志及饮食,易产生气机不畅,如郁病、失眠、梅核气、惊恐等,现代研究此类体质易生肿瘤。Qi stagnation constitution is a physical state formed due to long-term emotional depression and stagnation of Qi, with introverted and unstable personality, melancholy and fragility, sensitivity and suspicion as the main manifestations. People in this physical state are mostly middle-aged and young people, and more common in women. They are often lonely and introverted, easily sentimental, and narrow-minded. The main disease of people with Qi stagnation constitution is the liver, and also affects the heart, stomach, large intestine, and small intestine. It is easy to hurt emotions and diet, and it is easy to produce Qi stagnation, such as depression, insomnia, plum pit qi, panic, etc. Modern research shows that this kind of constitution is prone to tumors.
调理治疗宜调畅情志,疏通气机。气虚体质常出现:形体消瘦或偏胖,面色苍白,气短懒言,体倦乏力,常自汗出,动则尤甚,舌淡红,舌边有齿痕,苔白,脉虚弱。五脏气虚在临床上均可见,以心肺脾肾常见,除上述气虚证常见临床表现外,同时并见心、肺、脾、肾气虚的相应病变而见不同症状。发病倾向:易患感冒、气虚眩晕、内脏下垂,平素抵抗力弱,病后康复缓慢。Conditioning treatment should be used to regulate emotions and unblock the Qi. Qi deficiency constitution often presents: thin or slightly fat body, pale complexion, shortness of breath and laziness, fatigue, frequent spontaneous sweating, especially when moving, pale red tongue, tooth marks on the tongue edge, white fur, weak pulse. Qi deficiency of the five internal organs can be seen clinically, and the heart, lungs, spleen and kidneys are common. In addition to the common clinical manifestations of qi deficiency syndrome mentioned above, the corresponding lesions of heart, lungs, spleen and kidney qi deficiency are also seen with different symptoms. Tendency to disease: prone to colds, qi deficiency dizziness, visceral ptosis, weak resistance, and slow recovery after illness.
4.2本发明中药组合物穴位敷贴组方分析4.2 Analysis of the formula of the Chinese medicine composition for acupoint application of the present invention
本发明中药组合物穴位敷贴是由张晓天教授针对气郁体质的特点,结合经络、穴位、药物的特性,加以融合自主研发而成。其主要组成成分为柴胡、香附、枳壳、甘草、玫瑰花、绿萼梅(比例:1:1:1:0.5:0.5:0.5),全方共凑疏肝理气、行气调经、活血散瘀之功。The Chinese medicine composition acupoint application of the present invention is independently developed by Professor Zhang Xiaotian based on the characteristics of qi stagnation constitution, combined with the characteristics of meridians, acupoints and drugs. Its main components are bupleurum, cyperus, fructus aurantii, liquorice, rose and green calyx plum (ratio: 1:1:1:0.5:0.5:0.5), and the whole formula has the functions of soothing the liver and regulating qi, promoting qi and regulating menstruation, and promoting blood circulation and removing blood stasis.
柴胡:味苦、辛,性微寒,归肝、胆经。解表退热、疏肝解郁、升举阳气为治肝气郁结之要药,常用于治疗肝失疏泄、气机郁阻所致的胸胁或少腹胀痛、情志抑郁、妇女月经失调、痛经等症。Bupleurum: bitter and pungent in taste, slightly cold in nature, and enters the liver and gallbladder meridians. It is an essential medicine for treating liver qi stagnation, and can relieve fever, relieve liver qi depression, and raise yang qi. It is often used to treat chest and flank or lower abdominal distension and pain caused by liver failure to release qi, depression, menstrual disorders, and dysmenorrhea in women.
香附:味辛、微苦、微甘,性平。归肝、脾、三焦经。疏肝解郁,理气宽中,调经止痛。用于肝郁气滞、胸胁胀痛、疝气疼痛、乳房胀痛、脾胃气滞、脘腹痞闷、胀满疼痛、月经不调、经闭痛经。香附疏肝解郁之效佳,为肝行气、解郁之要药,临床常与柴胡、枳壳等配伍同用。Cyperus rotundus: Spicy, slightly bitter, slightly sweet, neutral in nature. It enters the liver, spleen, and triple burner meridians. It soothes the liver and relieves depression, regulates qi and relieves fullness, regulates menstruation and relieves pain. It is used for liver depression and qi stagnation, chest and flank pain, hernia pain, breast pain, spleen and stomach qi stagnation, abdominal distension, fullness and pain, irregular menstruation, amenorrhea and dysmenorrhea. Cyperus rotundus has a good effect of soothing the liver and relieving depression. It is an important medicine for promoting qi and relieving depression in the liver. It is often used in combination with Bupleurum chinense and Citrus aurantium in clinical practice.
枳壳:性味苦、辛、酸,微寒。归脾、胃经。具有理气宽中,行滞消胀的功效。临床多用于治疗胸胁气滞,胀满疼痛,食积不化,痰饮内停,脏器下垂。Citrus aurantium: bitter, pungent, sour, slightly cold in nature. It enters the spleen and stomach meridians. It has the effects of regulating qi, relieving fullness, and relieving stagnation and swelling. It is often used clinically to treat chest and flank qi stagnation, fullness and pain, indigestion, phlegm and fluid retention, and sagging organs.
甘草:性平,味甘。归心经、胃经、脾经、肺经。补脾益气、止咳祛痰、缓急定痛、调和药性。Licorice: neutral in nature, sweet in taste. Enters the heart meridian, stomach meridian, spleen meridian, and lung meridian. It nourishes the spleen and replenishes qi, relieves cough and expectoration, relieves urgency and pain, and harmonizes the properties of the medicine.
玫瑰花:性温,味甘、微苦,归肝经、脾经。行气解郁,和气止痛。临床主治肝胃气痛、月经不调、肝风头痛、肝郁吐血、慢性胆囊炎、气郁胸闷。Rose: warm in nature, sweet and slightly bitter in taste, belongs to the liver meridian and spleen meridian. It promotes qi and relieves depression, harmonizes qi and relieves pain. It is mainly used in clinical treatment of liver and stomach qi pain, menstrual disorders, liver wind headache, liver depression and vomiting blood, chronic cholecystitis, and chest tightness caused by qi depression.
绿萼梅:味微酸、涩,性平。归肝、胃、肺经。其芳香行气入肝胃,是治疗肝胃气痛的良药,也常用于化解情绪抑郁、开胸顺气、化痰散结,是肝气郁结者的保健佳品。适用于肝胃气滞所致的胁肋胀痛、脘腹痞满、嗳气、食欲不振、胃痛、消化不良者。情志不舒、肝气郁滞、痰气郁结所致心情烦躁郁闷、神经衰弱、梅核气、咽喉不爽、慢性咽炎者。Green-calyx plum: slightly sour and astringent, neutral in nature. Enters the liver, stomach, and lung meridians. Its aromatic aroma promotes the flow of qi into the liver and stomach, making it a good medicine for treating liver and stomach qi pain. It is also often used to resolve depression, open the chest and relieve qi, resolve phlegm and disperse knots, and is a good health product for people with liver qi stagnation. It is suitable for people with flank pain, abdominal distension, belching, loss of appetite, stomach pain, and indigestion caused by liver and stomach qi stagnation. It is suitable for people with irritability, depression, neurasthenia, plum pit qi, sore throat, and chronic pharyngitis caused by emotional discomfort, liver qi stagnation, and phlegm qi stagnation.
4.3选穴分析4.3 Acupoint Selection Analysis
选穴以膻中、肝俞为主,膻中为心包络经气聚集之处,《黄帝内经》中提到:“膻中者,臣使之官,喜乐出焉。”现代研究表明,刺激该穴可通过调节神经功能,松弛平滑肌,扩张冠状血管及消化道内腔径等作用,以对各类气病达到有效的治疗目的。肝俞为肝的背俞穴,《千金方》:“肝俞、脾俞、志室,主两胁急痛。”现代常用于治疗急慢性肝炎、胆囊炎、结膜炎、夜盲症、近视等。二穴合用宽胸理气,活血止痛,除痹通络之功,从而改善气郁体质偏颇人群的体质状态。The acupoints selected are mainly Tanzhong and Ganshu. Tanzhong is the place where the pericardium meridian qi gathers. The Yellow Emperor's Classic of Internal Medicine mentions: "Tanzhong is the official of the minister, and joy comes out of it." Modern research shows that stimulating this acupoint can effectively treat various qi diseases by regulating nerve function, relaxing smooth muscles, dilating coronary blood vessels and the diameter of the digestive tract. Ganshu is the back-shu point of the liver. "Qianjin Fang" says: "Ganshu, Pishu, Zhishi, the main two flank pain." It is commonly used in modern times to treat acute and chronic hepatitis, cholecystitis, conjunctivitis, night blindness, myopia, etc. The two acupoints are used together to widen the chest and regulate qi, promote blood circulation and relieve pain, and remove numbness and dredge the meridians, thereby improving the physical condition of people with qi stagnation constitution bias.
实施例34动物实验Example 34 Animal Experiment
1.材料与方法1. Materials and Methods
1.1实验材料1.1 Experimental Materials
1.1.1实验动物1.1.1 Experimental animals
SPF级Sprague-Dawley(SD)雄性小鼠40只,体质量(200±20)g,由(上海斯莱克实验动物有限公司)提供,饲养于恒温(22±1)℃和12∶12固定照明节律的环境下,并可自由摄取食物和水。Forty SPF Sprague-Dawley (SD) male mice weighing (200±20) g were provided by Shanghai SLAC Laboratory Animal Co., Ltd. They were housed in an environment with a constant temperature of (22±1)°C and a fixed lighting rhythm of 12:12, and had free access to food and water.
1.1.2实验药物本发明组:柴胡15份、香附15份、枳壳15份、甘草7.5份、玫瑰花7.5份、绿萼梅7.5份对照组1:柴胡15份、香橼15份、枳壳15份、生麦芽7.5份、玫瑰花7.5份、绿萼梅7.5份对照组2:柴胡15份、香附15份、枳壳15份、生麦芽7.5份、月季花7.5份、绿萼梅7.5份对照组3:柴胡15份、香橼15份、枳壳15份、甘草7.5份、月季花7.5份、绿萼梅7.5份1.1.2 Experimental drugs The present invention group: 15 parts of bupleurum, 15 parts of cyperus, 15 parts of aurantium, 7.5 parts of liquorice, 7.5 parts of rose, 7.5 parts of green-calyx plum Control group 1: 15 parts of bupleurum, 15 parts of citron, 15 parts of aurantium, 7.5 parts of raw malt, 7.5 parts of rose, 7.5 parts of green-calyx plum Control group 2: 15 parts of bupleurum, 15 parts of cyperus, 15 parts of aurantium, 7.5 parts of raw malt, 7.5 parts of rose, 7.5 parts of green-calyx plum Control group 3: 15 parts of bupleurum, 15 parts of citron, 15 parts of aurantium, 7.5 parts of liquorice, 7.5 parts of rose, 7.5 parts of green-calyx plum
1.1.3主要试剂:8%Na2S,75%的酒精;1.1.3 Main reagents: 8% Na 2 S, 75% alcohol;
1.1.4主要仪器:量筒;秒表。1.1.4 Main instruments: measuring cylinder; stopwatch.
1.2实验方法1.2 Experimental methods
1.2.1实验分组:40只大鼠依据随机数字表法分为:本发明组、对照组1、对照组2、对照组3,每组10只。1.2.1 Experimental groups: 40 rats were divided into the present invention group, control group 1, control group 2, and control group 3 according to the random number table method, with 10 rats in each group.
1.2.2气郁体质小鼠模型制造:参照朱清静(熊振芳,朱清静.柴胡疏肝散对慢性束缚应激性肝郁证大鼠的影响[J].中国中西医结合消化杂志,2004,(04):220-221.)、唐已婷(唐已婷,陈家旭.三种中药复方对慢性束缚应激大鼠下丘脑-垂体-肾上腺轴的调节[J].北京中医药大学学报,2002(03):23-26.)等的方法,实验开始时即给予束缚法,将大鼠放入束缚盒内,调节前端活动部位到合适的位置,使大鼠不产生强烈反抗的紧张程度,每天6h(9:00~15:00),连续6周。表明造模成功。1.2.2 The model of Qi-stagnation constitution mice was established by referring to the methods of Zhu Qingjing (Xiong Zhenfang, Zhu Qingjing. Effects of Chaihu Shugan Powder on rats with chronic restraint stress-induced liver depression syndrome [J]. Chinese Journal of Integrated Traditional and Western Medicine for Digestion, 2004, (04): 220-221.), Tang Yiting (Tang Yiting, Chen Jiaxu. Regulation of hypothalamus-pituitary-adrenal axis in rats with chronic restraint stress by three Chinese herbal compound prescriptions [J]. Journal of Beijing University of Chinese Medicine, 2002 (03): 23-26.). At the beginning of the experiment, the rats were restrained and placed in the restraint box. The front end of the active part was adjusted to a suitable position so that the rats would not produce strong resistance to the tension. The restraint was performed for 6 hours every day (9:00-15:00) for 6 consecutive weeks. This indicated that the model was successfully established.
1.2.3给药方法:1.2.3 Method of administration:
贴敷本发明组、贴敷对照组1、贴敷对照组2、贴敷对照组3:Patching group of the present invention, patch control group 1, patch control group 2, patch control group 3:
贴敷本发明组:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷本发明组(柴胡15份、香附15份、枳壳15份、甘草7.5份、玫瑰花7.5份、绿萼梅7.5份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.3克)贴敷8h后取掉,每日1次,共贴敷20次。Patching group of the present invention: Depilate the back of the mouse with 8% Na2S, the area is about 4cm×4cm, and after local disinfection with 75% alcohol, the patch group of the present invention (15 parts of Bupleurum, 15 parts of Cyperus, 15 parts of Citrus aurantium, 7.5 parts of Licorice, 7.5 parts of Rose, 7.5 parts of Prunus mume) is fixed on the depilated area (Tanzhong, Ganshu). Then press gently twice, and then wrap the chest and back with a self-adhesive tape to fix it. (Each piece (drug core) is about 0.3 grams) Remove it after 8 hours of application, once a day, a total of 20 times.
贴敷对照组1:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷对照组1(柴胡15份、香橼15份、枳壳15份、生麦芽7.5份、玫瑰花7.5份、绿萼梅7.5份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.3克)贴敷8h后取掉,每日1次,共贴敷20次。Patching control group 1: Depilate the back of the mouse with 8% Na 2 S, the area is about 4cm×4cm, and after local disinfection with 75% alcohol, apply the patch control group 1 (15 parts of Bupleurum, 15 parts of Citron, 15 parts of Citrus aurantium, 7.5 parts of Malt, 7.5 parts of Rose, 7.5 parts of Prunus mume) to the depilated area (Tanzhong, Ganshu). Then press gently twice, and then wrap the chest and back with a self-adhesive tape to fix it. (Each piece (core) is about 0.3 grams) Remove it after 8 hours of application, once a day, a total of 20 times.
贴敷对照组2:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷对照组2(柴胡15份、香附15份、枳壳15份、生麦芽7.5份、月季花7.5份、绿萼梅7.5份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.3克)贴敷8h后取掉,每日1次,共贴敷20次。Patching control group 2: Depilate the back of the mouse with 8% Na 2 S, the area is about 4cm×4cm, and after local disinfection with 75% alcohol, apply the patch control group 2 (15 parts of Bupleurum, 15 parts of Cyperus, 15 parts of Citrus aurantium, 7.5 parts of Malt, 7.5 parts of Rose, 7.5 parts of Prunus mume) to the depilated area (Tanzhong, Ganshu). Then press gently twice, and then wrap the chest and back with adhesive tape to fix. (Each piece (drug core) is about 0.3 grams) Remove it after 8 hours of application, once a day, a total of 20 times.
贴敷对照组3:将小鼠背部用8%Na2S脱毛,面积约为4cm×4cm,用75%的酒精局部消毒后,将贴敷对照组3(柴胡15份、香橼15份、枳壳15份、甘草7.5份、月季花7.5份、绿萼梅7.5份)贴固定于脱毛处(膻中、肝俞)。然后轻轻按压2次,再用不干胶布缠绕胸背固定。(每片(药芯)约0.3克)贴敷8h后取掉,每日1次,共贴敷20次。Patching control group 3: Depilate the back of the mouse with 8% Na2S, the area is about 4cm×4cm, and after local disinfection with 75% alcohol, apply the patch control group 3 (15 parts of Bupleurum, 15 parts of Citron, 15 parts of Citrus aurantium, 7.5 parts of Licorice, 7.5 parts of Rose, 7.5 parts of Prunus mume) to the depilated area (Tanzhong, Ganshu). Then press gently twice, and then wrap the chest and back with adhesive tape to fix. (Each piece (drug core) is about 0.3 grams) Remove it after 8 hours of application, once a day, a total of 20 times.
1.2.4观察检测指标1.2.4 Observation and testing indicators
小鼠强迫游泳试验:量筒内装21~23℃水10cm,量筒之间放置一个不透明板,防止小鼠彼此看到。末次灌药后1小时,小鼠被投入量筒,并滞留6min,计算后4min的不动时间,五只小鼠同时测量。判断不动的标准:停止挣扎,垂直体位,不动漂浮,仅做一些必要的活动使它的头露出水面。Mouse forced swimming test: 10 cm of 21-23℃ water is placed in a measuring cylinder, and an opaque plate is placed between the measuring cylinders to prevent the mice from seeing each other. One hour after the last injection, the mouse is put into the measuring cylinder and stays for 6 minutes. The immobility time after the last 4 minutes is calculated, and five mice are measured at the same time. The criteria for judging immobility: stop struggling, vertical position, float without moving, and only do some necessary activities to keep its head above water.
小鼠悬尾试验:强迫游泳后第3天,末次灌药后1小时,用胶带在距离小鼠尾尖30mm处将之固定于水平放置的棒状物上,中间用板隔开,防止彼此看到对方。小鼠距离最近的物体大约100mm。悬挂6min,记录后4min的不动时间,每次测量5只。Mouse tail suspension test: On the third day after forced swimming and one hour after the last drug administration, use tape to fix the mouse to a horizontally placed rod 30 mm away from the tip of the tail, with a board in the middle to prevent each other from seeing each other. The mouse is about 100 mm away from the nearest object. Hang for 6 minutes, record the immobility time of the last 4 minutes, and measure 5 mice each time.
1.2.5统计学处理1.2.5 Statistical analysis
采用SPSS10.0软件,进行单因素方差分析,两组间比较用t检验。SPSS10.0 software was used for one-way analysis of variance, and t-test was used for comparison between the two groups.
2.结果2. Results
表11不同贴对小鼠强迫游泳模型不动时间的影响(x±s)Table 11 Effects of different patches on immobility time in the forced swimming model of mice (x±s)
本发明组与对照组1、对照组3相比P<0.05,本发明组与对照组2相比P<0.01。The difference between the present invention group and control group 1 and control group 3 was P<0.05, and the difference between the present invention group and control group 2 was P<0.01.
表12不同贴对小鼠悬尾模型不动时间的影响(x±s)Table 12 Effects of different patches on the immobility time of the tail suspension model in mice (x±s)
本发明组与对照组1、对照组2相比P<0.05,本发明组与对照组1相比P<0.01。Compared with control group 1 and control group 2, the difference between the present invention group and control group 1 was P<0.05; compared with control group 1, the difference between the present invention group and control group 1 was P<0.01.
在小鼠小鼠强迫游泳中显示了减少不动时间的趋势。本实验结果表明:本发明具有改善气郁体质作用。The mice showed a tendency to reduce the immobility time in forced swimming. The experimental results show that the present invention has the effect of improving qi stagnation constitution.
一种改善气虚体质的中药组合物及其制备方法和应用实施例A Chinese medicine composition for improving qi deficiency constitution and its preparation method and application example
实施例35本发明中药组合物的制备(一)Example 35 Preparation of the Chinese medicine composition of the present invention (I)
按比例1:1:1:0.5:1:0.1称取原料药黄芪15份、炒白术15份、防风15份、陈皮7.5份、太子参15份、人参1.5份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 15 parts of raw materials astragalus, 15 parts of stir-fried atractylodes, 15 parts of siler, 7.5 parts of dried tangerine peel, 15 parts of pseudoginseng, and 1.5 parts of ginseng.
实施例36本发明中药组合物的制备(二)Example 36 Preparation of the Chinese medicine composition of the present invention (II)
按比例1:1:1:0.5:1:0.1称取原料药黄芪10份、炒白术10份、防风10份、陈皮5份、太子参10份、人参1份。Weigh 10 parts of raw materials astragalus, 10 parts of stir-fried atractylodes, 10 parts of siler, 5 parts of dried tangerine peel, 10 parts of pseudoginseng, and 1 part of ginseng in the ratio of 1:1:1:0.5:1:0.1.
实施例37本发明中药组合物的制备(三)Example 37 Preparation of the Chinese medicine composition of the present invention (III)
按比例1:1:1:0.5:1:0.1称取原料药黄芪20份、炒白术20份、防风20份、陈皮10份、太子参20份、人参2份。Weigh 20 parts of raw materials astragalus, 20 parts of stir-fried atractylodes, 20 parts of siler, 10 parts of dried tangerine peel, 20 parts of pseudoginseng, and 2 parts of ginseng in the ratio of 1:1:1:0.5:1:0.1.
实施例38本发明中药组合物的制备(四)Example 38 Preparation of the Chinese medicine composition of the present invention (IV)
按比例1:1:1:0.5:1:0.1称取原料药黄芪12份、炒白术12份、防风12份、陈皮6份、太子参12份、人参1.2份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 12 parts of raw materials astragalus, 12 parts of stir-fried atractylodes, 12 parts of siler, 6 parts of dried tangerine peel, 12 parts of pseudoginseng, and 1.2 parts of ginseng.
实施例39本发明中药组合物的制备(五)Example 39 Preparation of the Chinese medicine composition of the present invention (V)
按比例1:1:1:0.5:1:0.1称取原料药黄芪18份、炒白术18份、防风18份、陈皮9份、太子参18份、人参1.8份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 18 parts of raw materials astragalus, 18 parts of stir-fried atractylodes, 18 parts of siler, 9 parts of dried tangerine peel, 18 parts of pseudoginseng, and 1.8 parts of ginseng.
实施例40本发明中药组合物的制备(六)Example 40 Preparation of the Chinese medicine composition of the present invention (VI)
按比例1:1:1:0.5:1:0.1称取原料药黄芪11份、炒白术11份、防风11份、陈皮5.5份、太子参11份、人参1.1份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 11 parts of raw materials astragalus, 11 parts of stir-fried atractylodes, 11 parts of siler, 5.5 parts of dried tangerine peel, 11 parts of pseudoginseng, and 1.1 parts of ginseng.
实施例41本发明中药组合物的制备(七)Example 41 Preparation of the Chinese medicine composition of the present invention (VII)
按比例1:1:1:0.5:1:0.1称取原料药黄芪13份、炒白术13份、防风13份、陈皮6.5份、太子参13份、人参1.3份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 13 parts of raw materials astragalus, 13 parts of stir-fried atractylodes, 13 parts of siler, 6.5 parts of dried tangerine peel, 13 parts of pseudoginseng, and 1.3 parts of ginseng.
实施例42本发明中药组合物的制备(八)Example 42 Preparation of the Chinese medicine composition of the present invention (VIII)
按比例1:1:1:0.5:1:0.1称取原料药黄芪14份、炒白术14份、防风14份、陈皮7份、太子参14份、人参1.4份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 14 parts of raw materials astragalus, 14 parts of stir-fried atractylodes, 14 parts of siler, 7 parts of dried tangerine peel, 14 parts of pseudoginseng, and 1.4 parts of ginseng.
实施例43本发明中药组合物的制备(九)Example 43 Preparation of the Chinese medicine composition of the present invention (IX)
按比例1:1:1:0.5:1:0.1称取原料药黄芪16份、炒白术16份、防风16份、陈皮8份、太子参16份、人参1.6份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 16 parts of raw materials astragalus, 16 parts of stir-fried atractylodes, 16 parts of siler, 8 parts of dried tangerine peel, 16 parts of pseudoginseng, and 1.6 parts of ginseng.
实施例44本发明中药组合物的制备(十)Example 44 Preparation of the Chinese medicine composition of the present invention (X)
按比例1:1:1:0.5:1:0.1称取原料药黄芪19份、炒白术19份、防风19份、陈皮9.5份、太子参19份、人参1.9份。According to the ratio of 1:1:1:0.5:1:0.1, weigh 19 parts of raw materials astragalus, 19 parts of stir-fried atractylodes, 19 parts of siler, 9.5 parts of dried tangerine peel, 19 parts of pseudoginseng, and 1.9 parts of ginseng.
实施例45本发明中药组合物穴位敷贴的制备Example 45 Preparation of acupuncture point application of the Chinese medicine composition of the present invention
(1)实施例35-44任一所述的重量份配比称取各原料药,并打碎成粉,再混合适量姜汁和热熔胶基质调和成膏状,中药粉与热熔胶基质比例一般为1:3。(1) Weigh each raw material medicine in the weight proportion described in any one of Examples 35-44, crush it into powder, and then mix it with appropriate amount of ginger juice and hot melt adhesive matrix to form a paste. The ratio of Chinese medicine powder to hot melt adhesive matrix is generally 1:3.
(2)将上述混合物先制作成流浸膏,并用适宜的溶剂(水中加20%-25%的乙醇)提取,后蒸去部分溶剂,以将浓度调整至每1ml相当于药材1g。(2) The above mixture is first made into a fluid extract, and extracted with a suitable solvent (20%-25% ethanol in water), and then part of the solvent is evaporated to adjust the concentration to 1 ml equivalent to 1 g of medicinal material.
(3)将医用压敏热溶胶1kg,放入锅内加热至80℃左右融化,后降温至60-70℃左右时将药粉徐徐加入搅拌均匀,40℃左右时加入流浸膏、氮酮(透皮剂其中基质和氮酮的比例在1000:10左右),持续搅拌,然后摊膏,制成直径4-5cm、厚度约2-3mm的药饼。(3) Place 1 kg of medical pressure-sensitive hot melt adhesive in a pot and heat to about 80°C to melt. When the temperature drops to about 60-70°C, slowly add the drug powder and stir evenly. When the temperature is about 40°C, add the fluid extract and azone (the ratio of the base to azone in the transdermal agent is about 1000:10), continue stirring, and then spread the paste to make a drug cake with a diameter of 4-5 cm and a thickness of about 2-3 mm.
实施例46本发明中药组合物贴剂的制备Example 46 Preparation of the Chinese medicine composition patch of the present invention
(1)按照实施例35-44任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 35-44, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,除去水溶液,所得浸膏真空干燥;(2) the above-mentioned drug solution is concentrated under vacuum to remove the aqueous solution, and the obtained extract is vacuum dried;
(3)称取上述浸膏2g,加入药用甘油2-6ml,调成糊状,均匀的摊铺在固定大小的方形医用胶布上,四周边缘留出一定大小来固定胶布。(3) Weigh 2 g of the above extract, add 2-6 ml of medical glycerin, mix into a paste, and spread evenly on a square medical tape of a fixed size, leaving a certain size around the edges to fix the tape.
实施例47本发明中药组合物软膏剂的制备Example 47 Preparation of the Chinese medicine composition ointment of the present invention
(1)按照实施例35-44任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 35-44, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)在浓缩液中加入蜂蜡和黄凡士林,温火煎熬搅拌,冷却成膏状物。(3) Add beeswax and yellow vaseline to the concentrate, simmer and stir over low heat, and cool until it becomes a paste.
实施例48本发明中药组合物凝胶剂的制备Example 48 Preparation of the Chinese medicine composition gel of the present invention
(1)按照实施例35-44任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 35-44, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)将卡波姆加入甘油中研磨使其润湿,再加入少量蒸馏水研磨后,移到量杯中,另取三乙醇胺、羟苯乙酯、蒸馏水适量使其溶解,搅拌成凝胶状,再加适量蒸馏水搅匀;加入上述浓缩液,研磨均匀即得。(3) Add carbomer to glycerin and grind it to moisten it. Then add a small amount of distilled water to grind it. Transfer it to a measuring cup, take appropriate amounts of triethanolamine, ethylparaben, and distilled water to dissolve them, stir them into a gel, add appropriate amount of distilled water and stir evenly; add the above concentrate and grind evenly to obtain the product.
实施例49本发明中药组合物巴布剂的制备Example 49 Preparation of the Chinese medicine composition cataplasm of the present invention
(1)按照实施例35-44任一所述的重量份配比称取各原料药,加入8-10倍量的水,煎煮两次,每次60分钟,趁热过滤,合并两次煎煮药液备用;(1) Weigh each raw material drug according to the weight ratio described in any one of Examples 35-44, add 8-10 times the amount of water, decoct twice, each time for 60 minutes, filter while hot, and combine the two decoctions for later use;
(2)上述药液经真空减压浓缩,得到药液浓缩液;(2) the above-mentioned liquid medicine is concentrated by vacuum decompression to obtain a liquid medicine concentrate;
(3)在浓缩液中加入山梨醇、甘油等常规巴布剂基质,搅匀,涂布于支持层,加入保护层即得。(3) Add sorbitol, glycerol and other conventional poultice bases to the concentrate, stir well, apply to the support layer, and add a protective layer.
实施例50本发明中药组合物穴位敷贴的临床实验Example 50 Clinical Experiment on Acupoint Application of the Chinese Medicine Composition of the Present Invention
1研究对象1 Research subjects
1.1样本来源1.1 Sample Source
本实验样本来源自2020年6月至2021年3月就诊于上海中医药大学附属曙光医院门诊及住院部中符合纳入标准的中医气虚体质和慢性腹泻的患者30例,并随机分成对照组及治疗组患者各15例。The samples for this experiment were derived from 30 patients with TCM Qi deficiency constitution and chronic diarrhea who met the inclusion criteria and visited the outpatient and inpatient departments of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from June 2020 to March 2021. They were randomly divided into a control group and a treatment group with 15 patients in each group.
1.2诊断标准1.2 Diagnostic criteria
1.2.1中医气虚体质诊断标准1.2.1 Diagnostic criteria for Qi deficiency constitution in traditional Chinese medicine
根据2009年4月9日中国中医药出版社出版的《中医体质分类与判定》积分量表转化分结果并结合医生判断,判断受试者体质为气虚体质。According to the conversion results of the integral scale in "Classification and Determination of Constitution in Traditional Chinese Medicine" published by China Traditional Chinese Medicine Press on April 9, 2009 and combined with the doctor's judgment, the subject's constitution was judged to be Qi deficiency constitution.
气虚体质判定问卷:①您容易疲劳吗?②您容易气短(呼吸短促,接不上气)吗?③您容易心慌吗?④您容易头晕或者站起来晕眩吗?⑤您比别人容易患感冒吗?⑥您喜欢安静、懒得说话吗?⑦您说话声音低弱无力吗?⑧您活动量稍大就容易出虚汗吗?Questionnaire for determining qi deficiency constitution: ①Are you easily fatigued? ②Are you easily short of breath (shortness of breath, choking)? ③Are you easily flustered? ④Are you easily dizzy or feel dizzy when standing up? ⑤Are you more likely to catch a cold than others? ⑥Do you like quietness and are too lazy to talk? ⑦Do you speak in a low, weak voice? ⑧Do you sweat easily when you are a little more active?
判定标准如下表:The judgment criteria are as follows:
表13中医体质判定标准表Table 13 Standards for determining TCM constitution
注:1.计分方法:每个条目按照“没有(或)不”“很少”“有时”“经常”“总是”分别依次计1、2、3、4、5分。2.转化分数=(各条目总分-条目数)/(条目数×4)×100;范围为0-100分。Note: 1. Scoring method: Each item is scored 1, 2, 3, 4, and 5 points respectively according to "never (or) not", "rarely", "sometimes", "often", and "always". 2. Conversion score = (total score of each item - number of items) / (number of items × 4) × 100; the range is 0-100 points.
本实验中将气虚体质转化分大于等于40分判定为气虚体质。In this experiment, people with a Qi deficiency constitution conversion score of 40 points or more were judged as having a Qi deficiency constitution.
2.2治疗方案2.2 Treatment options
治疗组治疗方案为使用本发明中药组合物穴位敷贴,分为2个疗程,共60天。The treatment plan for the treatment group is to use the Chinese medicine composition of the present invention for acupoint application, which is divided into 2 courses of treatment, a total of 60 days.
本发明中药组合物穴位敷贴:由上海中医药大学附属曙光医院治未病中心针对气虚体质的特点,结合经络、穴位、药物的特性,加以融合自主研发而成。其主要组成成分为黄芪、炒白术、防风、陈皮、太子参、人参(比例:1:1:1:0.5:1:0.1),由山东煜和堂药业有限公司按照制作流程标准统一制作(生产批号:20191002),规格为4cm×4cm/片,每片(药芯)约0.5克。The Chinese medicine composition acupuncture patch of the present invention is independently developed by the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, based on the characteristics of qi deficiency constitution, combined with the characteristics of meridians, acupuncture points, and drugs. Its main components are astragalus, stir-fried white atractylodes, saposhnikovia, tangerine peel, Pseudostellaria heterophylla, and ginseng (ratio: 1:1:1:0.5:1:0.1), and is uniformly produced by Shandong Yuhetang Pharmaceutical Co., Ltd. according to the production process standards (production batch number: 20191002), with a specification of 4cm×4cm/piece, and each piece (drug core) is about 0.5 grams.
制作流程:①将上述所需中药颗粒剂按比例1:1:1:0.5:1:0.1配比并打碎成粉,再混合热熔胶基质,中药粉与热熔胶基质比例一般为1:3。②将上述混合物先制作成流浸膏,并用适宜的溶剂(水中加20%-25%的乙醇)提取,后蒸去部分溶剂,以将浓度调整至每1ml相当于药材1g。③将医用压敏热溶胶1kg,放入锅内加热至80℃左右融化,后降温至60-70℃左右时将药粉徐徐加入搅拌均匀,40℃左右时加入流浸膏、氮酮(透皮剂其中基质和氮酮的比例在1000:10左右),持续搅拌,然后摊膏。Production process: ① Mix the required Chinese medicine granules in the ratio of 1:1:1:0.5:1:0.1 and crush them into powder, then mix with the hot melt adhesive matrix. The ratio of Chinese medicine powder to hot melt adhesive matrix is generally 1:3. ② First make the above mixture into a fluid extract, and extract it with a suitable solvent (20%-25% ethanol in water), and then evaporate part of the solvent to adjust the concentration to 1g of medicinal materials per 1ml. ③ Put 1kg of medical pressure-sensitive hot melt adhesive into a pot and heat it to about 80℃ to melt. After cooling to about 60-70℃, slowly add the powder and stir evenly. At about 40℃, add the fluid extract and azone (the ratio of the matrix and azone in the transdermal agent is about 1000:10), continue stirring, and then spread the paste.
使用方法:嘱患者全身沐浴或擦洗肢体后,保持皮肤温润,将本发明中药组合物穴位敷贴贴于人体气海、脾俞、足三里,每次4-8小时,每一周三次。Usage: ask the patient to bathe the whole body or scrub the limbs, keep the skin warm, and apply the Chinese medicine composition of the present invention to the Qihai, Pishu and Zusanli acupoints of the human body for 4-8 hours each time, three times a week.
2.3中医体质评分情况2.3 TCM Constitution Scoring
比较观察两组干预对象在干预前后组内及组间各体质转化分的变化情况,其中中医气虚体质转化分为主要疗效指标。The changes of constitution transformation scores within and between the two groups of intervention subjects before and after the intervention were compared and observed, among which the TCM Qi deficiency constitution transformation score was the main efficacy indicator.
2.4不良反应记录2.4 Adverse reaction records
观察使用本发明中药组合物穴位敷贴期间是否出现不良事件或敷贴药物的不良反应(如皮肤瘙痒、皮肤红肿热痛、皮肤破溃等),如有发生及时记录发生时间及处理措施。Observe whether adverse events or adverse reactions of the application drugs (such as skin itching, skin redness, swelling, heat and pain, skin ulceration, etc.) occur during the acupoint application of the Chinese medicine composition of the present invention. If any, record the time of occurrence and treatment measures in time.
2.5临床干预疗效判定标准2.5 Criteria for determining the efficacy of clinical interventions
2.5.1中医临床干预疗效判定标准2.5.1 Criteria for determining the efficacy of TCM clinical intervention
中医临床干预疗效判定依据中医气虚体质转化分进行评判,其标准参照2017年国家药品监督管理局发布的《中医病证诊断疗效标准》相关标准运用症状积分变化进行判定。The efficacy of TCM clinical intervention is judged based on the TCM Qi deficiency constitution transformation score. The standard refers to the relevant standards of the "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes" issued by the State Food and Drug Administration in 2017, and is judged using changes in symptom scores.
疗效指数(n)=治疗前后的症状积分差/治疗前的症状积分×100%。Therapeutic index (n) = difference in symptom scores before and after treatment/symptom scores before treatment × 100%.
①临床痊愈:临床症状、体征消失或基本消失,证候积分减少≥95%。① Clinical cure: clinical symptoms and signs disappear or basically disappear, and the syndrome score decreases by ≥95%.
②显效:临床症状、体征消失或基本消失,证候积分减少≥70%。② Markedly effective: clinical symptoms and signs disappeared or basically disappeared, and the syndrome score decreased by ≥70%.
③有效:临床症状、体征消失或基本消失,证候积分减少≥30,但<70%。③ Effective: Clinical symptoms and signs disappeared or almost disappeared, and the syndrome score decreased by ≥30 but <70%.
④无效:临床症状、体征均无明显改善,甚或加重,证候积分减少不足30%。④ Ineffective: There is no significant improvement in clinical symptoms and signs, or they may even worsen, and the symptom score decreases by less than 30%.
3.3体质转化分3.3 Physical Conversion Points
治疗后,两组患者的体质转化分均有降低,对照组与治疗前相比,差异不显著,P>0.05;治疗组在治疗前后,组内比较和组间比较,差异均有显著性,P<0.05。After treatment, the physical transformation scores of both groups of patients decreased. There was no significant difference in the control group compared with before treatment, P>0.05; there were significant differences in the treatment group before and after treatment, both within-group and between-group comparisons, P<0.05.
表14两组患者治疗前后中医气虚体质转化分比较Table 14 Comparison of TCM Qi deficiency constitution transformation scores between the two groups of patients before and after treatment
注:与治疗前比较,*P<0.05;与对照组比较,^P<0.05。Note: Compared with before treatment, *P<0.05; compared with control group, ^P<0.05.
3.3安全性指标的研究结果3.3 Research results of safety indicators
患者在治疗期间均未出现敷贴药物的不良反应(如皮肤瘙痒、皮肤红肿热痛、皮肤破溃等)。During the treatment period, no adverse reactions to the medication (such as skin itching, skin redness, swelling, heat and pain, skin ulceration, etc.) occurred in the patients.
4讨论4 Discussion
4.1气虚体质的概念及临床特征4.1 Concept and clinical characteristics of Qi deficiency constitution
气虚体质多因先天禀赋不足、长期饮食失调、情志失调、久病、劳累之后,年老体弱引起心、肺、脾、肾功能损伤,因心主血脉,肺主一身之气,肾藏元气,脾胃为“气生化之源”,因此气虚体质易导致推动血液运行作用减退,体内气的化生不足,机体防御外邪,护卫肌表,维护内脏位置功能减退的病证发生。Qi deficiency constitution is mostly caused by congenital deficiency, long-term eating disorders, emotional disorders, long-term illness, fatigue, and old age and physical weakness, which leads to damage to the heart, lung, spleen, and kidney functions. The heart controls the blood vessels, the lungs control the qi of the whole body, the kidneys store the original qi, and the spleen and stomach are the "source of qi generation and transformation". Therefore, qi deficiency constitution can easily lead to a decrease in the function of promoting blood circulation, insufficient qi generation in the body, and a decrease in the body's defense against external evil, protection of the skin, and maintenance of the position of internal organs.
气虚体质常出现:形体消瘦或偏胖,面色苍白,气短懒言,体倦乏力,常自汗出,动则尤甚,舌淡红,舌边有齿痕,苔白,脉虚弱。五脏气虚在临床上均可见,以心肺脾肾常见,除上述气虚证常见临床表现外,同时并见心、肺、脾、肾气虚的相应病变而见不同症状。发病倾向:易患感冒、气虚眩晕、内脏下垂,平素抵抗力弱,病后康复缓慢。Qi deficiency constitution often presents: thin or slightly fat body, pale complexion, shortness of breath, laziness, fatigue, frequent spontaneous sweating, especially when moving, pale red tongue, tooth marks on the tongue edge, white fur, weak pulse. Qi deficiency of the five internal organs can be seen clinically, and the heart, lungs, spleen and kidney are the most common. In addition to the common clinical manifestations of qi deficiency syndrome mentioned above, the corresponding lesions of heart, lungs, spleen and kidney qi deficiency are also seen, and different symptoms are seen. Tendency to disease: prone to colds, qi deficiency dizziness, visceral ptosis, weak resistance, and slow recovery after illness.
由于细胞因子与疲劳症状的出现密切相关,大多数气虚体质的人群存在免疫系统功能紊乱或免疫系统功能的下降。人体免疫功能的下降能够导致机体在防御、识别以及排除外来病原体和自身抗原性异物能力的下降,难以维持机体内环境生理平衡,导致疾病的产生。Since cytokines are closely related to the onset of fatigue symptoms, most people with Qi deficiency have immune system dysfunction or a decline in immune system function. A decline in human immune function can lead to a decline in the body's ability to defend, identify, and eliminate foreign pathogens and self-antigenic foreign bodies, making it difficult to maintain the physiological balance of the body's internal environment, leading to the occurrence of diseases.
4.2本发明中药组合物穴位敷贴组方分析4.2 Analysis of the formula of the Chinese medicine composition for acupoint application of the present invention
本发明中药组合物穴位敷贴是由张晓天教授针对痰湿体质的特点,结合经络、穴位、药物的特性,加以融合自主研发而成。其主要组成成分为黄芪、炒白术、防风、陈皮、太子参、人参(比例:1:1:1:0.5:1:0.1),全方共凑益气培元、补益脾肺、行气化滞之功。The Chinese medicine composition acupoint application of the present invention is independently developed by Professor Zhang Xiaotian based on the characteristics of phlegm-damp constitution, combined with the characteristics of meridians, acupoints and drugs. Its main components are astragalus, stir-fried white atractylodes, saposhnikovia, tangerine peel, Pseudostellaria baicalensis and ginseng (ratio: 1:1:1:0.5:1:0.1), and the whole formula has the functions of replenishing qi, nourishing the spleen and lungs, and promoting qi and removing stagnation.
黄芪:味甘,性微温;归脾、肺经。补气固表,托毒排脓,利尿,生肌。用于气虚乏力、久泻脱肛、自汗、水肿、子宫脱垂、慢性肾炎蛋白尿、糖尿病、疮口久不愈合。Astragalus: sweet, slightly warm; enters the spleen and lung meridians. It replenishes qi and strengthens the exterior, removes toxins and pus, promotes urination, and promotes tissue regeneration. It is used for qi deficiency and fatigue, chronic diarrhea and prolapse of the anus, spontaneous sweating, edema, uterine prolapse, proteinuria in chronic nephritis, diabetes, and wounds that do not heal for a long time.
白术:性温,味甘、苦。归脾经、胃经。健脾、益气、燥湿利水、止汗、安胎。属补虚药下属分类的补气药。Atractylodes macrocephala: warm in nature, sweet and bitter in taste. Enters the spleen meridian and stomach meridian. Strengthens the spleen, replenishes qi, dries dampness and promotes diuresis, stops sweating, and stabilizes pregnancy. It is a qi-tonifying drug under the category of tonic drugs.
防风:性温,味甘、辛。归膀胱经、肝经、脾经。发表、祛风、除湿。属解表药下分类辛温解表药。Saposhnikovia: warm in nature, sweet and pungent in taste. Enters the bladder meridian, liver meridian, spleen meridian. It has the functions of dispelling wind and removing dampness. It belongs to the category of pungent and warm antipyretic drugs under the category of antipyretic drugs.
陈皮:味辛、味苦,性温。归脾经、肺经。理气开胃,燥湿化痰,治脾胃病。属理气药。Tangerine peel: Spicy, bitter, warm in nature. Enters the spleen and lung meridians. Regulates qi and stimulates appetite, dries dampness and resolves phlegm, treats spleen and stomach diseases. It is a qi-regulating drug.
太子参:性平,味甘、微苦。归脾经、肺经。益气健脾、生津润肺。属补虚药下属分类的补气药。Radix Pseudostellariae: neutral in nature, sweet and slightly bitter in taste. Enters the spleen meridian and lung meridian. Replenishes qi and strengthens the spleen, produces body fluid and moistens the lungs. It is a qi-tonifying drug under the category of tonic drugs.
人参:性温,味甘、微苦。归心经、肺经、脾经、肾经。大补元气、复脉固脱、补脾益肺、生津安神。属补虚药下分类的补气药。Ginseng: warm in nature, sweet and slightly bitter in taste. It enters the heart meridian, lung meridian, spleen meridian, and kidney meridian. It greatly replenishes vital energy, restores pulse and consolidates the body, replenishes the spleen and lungs, and promotes the production of body fluids and calms the mind. It is a Qi-tonifying drug under the category of tonic drugs.
4.3选穴分析4.3 Acupoint Selection Analysis
选穴以气海、脾俞、足三里为主,脾俞为经气输注于背部的腧穴,气海、足三里均为补气培元的要穴,《铜人腧穴针灸图经》载:“气海者,是男子生气之海也。”此穴有培补元气,益肾固精,补益回阳。《千金要方》云:“若要安,三里常不干。”三穴合用增强补气强身,延年益寿之功,从而改善气虚体质偏颇人群的体质状态。The acupoints selected are mainly Qihai, Pishu and Zusanli. Pishu is the acupoint where the meridian qi is infused on the back. Qihai and Zusanli are both important acupoints for replenishing qi and nourishing the essence. The "Bronze Man Acupoint Acupoints and Acupuncture Illustrated Manual" states: "Qihai is the sea of vitality for men." This acupoint can nourish the original qi, strengthen the kidney and consolidate the essence, and replenish and restore yang. "Qianjin Yaofang" says: "If you want to be at peace, Sanli is always wet." The three acupoints are used together to enhance the function of replenishing qi and strengthening the body, prolonging life, and thus improve the physical condition of people with qi deficiency constitution.
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.
Claims (4)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210973140.1A CN115245549B (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis |
CN202310599686.XA CN116370560A (en) | 2022-08-15 | 2022-08-15 | Traditional Chinese medicine composition for improving qi stagnation constitution |
CN202310599692.5A CN116370539A (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving Qi-deficiency constitution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210973140.1A CN115245549B (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310599692.5A Division CN116370539A (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving Qi-deficiency constitution |
CN202310599686.XA Division CN116370560A (en) | 2022-08-15 | 2022-08-15 | Traditional Chinese medicine composition for improving qi stagnation constitution |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115245549A CN115245549A (en) | 2022-10-28 |
CN115245549B true CN115245549B (en) | 2023-07-25 |
Family
ID=83699231
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210973140.1A Active CN115245549B (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis |
CN202310599692.5A Pending CN116370539A (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving Qi-deficiency constitution |
CN202310599686.XA Pending CN116370560A (en) | 2022-08-15 | 2022-08-15 | Traditional Chinese medicine composition for improving qi stagnation constitution |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310599692.5A Pending CN116370539A (en) | 2022-08-15 | 2022-08-15 | A traditional Chinese medicine composition for improving Qi-deficiency constitution |
CN202310599686.XA Pending CN116370560A (en) | 2022-08-15 | 2022-08-15 | Traditional Chinese medicine composition for improving qi stagnation constitution |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN115245549B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536858A (en) * | 2013-11-01 | 2014-01-29 | 陈丽艳 | Medicine for treating rheumatoid arthritis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1957973A (en) * | 2005-11-03 | 2007-05-09 | 董斌 | Yuepingfeng effervesce granules, and preparation method |
CN102973758A (en) * | 2011-09-05 | 2013-03-20 | 彭军 | Traditional Chinese medicine composition for treating depression |
CN104127751A (en) * | 2014-08-22 | 2014-11-05 | 刘德学 | Traditional Chinese medicine for treating chronic bronchitis caused by phlegm-dampness lung attacking and preparation method thereof |
CN111249420A (en) * | 2020-03-27 | 2020-06-09 | 程亚伟 | Traditional Chinese medicine composition for regulating and treating qi-stagnation constitution and preparation and application thereof |
CN113599447A (en) * | 2021-09-26 | 2021-11-05 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof |
CN113713009A (en) * | 2021-10-14 | 2021-11-30 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for improving specific endowment constitution and preparation method and application thereof |
-
2022
- 2022-08-15 CN CN202210973140.1A patent/CN115245549B/en active Active
- 2022-08-15 CN CN202310599692.5A patent/CN116370539A/en active Pending
- 2022-08-15 CN CN202310599686.XA patent/CN116370560A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536858A (en) * | 2013-11-01 | 2014-01-29 | 陈丽艳 | Medicine for treating rheumatoid arthritis |
Non-Patent Citations (1)
Title |
---|
张小龙运用膏方治疗心系疾病经验介绍;章丹杰等;光明中医;第30卷(第1期);178-179 * |
Also Published As
Publication number | Publication date |
---|---|
CN116370560A (en) | 2023-07-04 |
CN115245549A (en) | 2022-10-28 |
CN116370539A (en) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104367879A (en) | Pharmaceutical composition for chickens' internal lesion caused by overexertion and preparation method of pharmaceutical composition | |
CN102416079A (en) | Chinese patent medicine for treating leucoderma | |
CN101234164B (en) | Pharmaceutical composition for improving skin oil-water balance and acne symptoms and preparation method thereof | |
CN102362950A (en) | Traditional Chinese medicine for treating leucoderma | |
CN104208418A (en) | Rosa laevigata michx health oral solution for securing essence, reducing urination and tonifying kidneys and preparation method thereof | |
CN111840419A (en) | Intelligent system preparation for conditioning physique and preventing and treating various skin diseases and preparation method | |
CN111840496A (en) | Intelligent system preparation for conditioning physique and preventing and treating various eczema diseases and preparation method | |
CN104225078A (en) | Traditional Chinese medicine composition and preparation method thereof for treatment of chloasma | |
CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
CN105213557A (en) | A kind of traditional Chinese medicine composition for treating eczema | |
CN101897933B (en) | Chinese patent medicament for treating leucoderma | |
CN118121656A (en) | Traditional Chinese medicine composition for treating chronic fatigue syndrome and preventing sub-health and preparation method thereof | |
CN102430013A (en) | Traditional Chinese medicine for treating leucoderma | |
CN115245549B (en) | A traditional Chinese medicine composition for improving damp-heat constitution gouty arthritis | |
CN103028060B (en) | Traditional Chinese medicine composition for treating infant acute eczema and preparation method of traditional Chinese medicine composition | |
CN102430097A (en) | Traditional Chinese medicine for treating leucoderma | |
CN106214997A (en) | A kind of Herba Taraxaci oral liquid of Elmination of toxicant and fat-lowering fat-reducing and preparation method thereof | |
CN117599125A (en) | A Chinese medicinal composition for supplementing calcium and strengthening bones for treating osteoporosis, and its preparation method and application | |
CN112717113B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and paste formula and application thereof | |
CN112043773A (en) | Intelligent system preparation for conditioning physique and preventing and treating various psoriasis and preparation method thereof | |
CN110559276A (en) | intelligent system plaster for conditioning physique and preventing and treating various types of diarrhea and preparation method | |
CN111905057A (en) | A Chinese medicinal composition for treating diabetes | |
CN115779043B (en) | A traditional Chinese medicine composition for treating female menopausal syndrome, preparation method and application thereof | |
CN117959394B (en) | Use of Shenqi Tongmai preparation in preparing medicine for preventing and treating diabetic neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |